## 1 RNA-seq analysis of skeletal muscle in motor neurone disease

## 2 cases and controls

- 3 Anna Freydenzon<sup>1,\*</sup>, Shivangi Wani<sup>1</sup>, Vanda Bharti<sup>1</sup>, Leanne M. Wallace<sup>1</sup>,
- 4 Anjali K. Henders<sup>1</sup>, Pamela A. McCombe<sup>2, 3</sup>, Robert D. Henderson<sup>2, 3</sup>, Frederik

- 7 1 Institute for Molecular Bioscience; The University of Queensland; St Lucia,
- 8 QLD, 4072; Australia
- 9 2 Centre for Clinical Research (CCR); The University of Queensland; Herston,
- 10 QLD, 4029; Australia
- 11 3 Department of Neurology; Royal Brisbane and Women's Hospital; Brisbane,
- 12 QLD, 4029; Australia
- 13 4 The School of Biomedical Sciences; The University of Queensland;
- 14 Brisbane, QLD, 4072; Australia
- 15 5 Queensland Brain Institute; The University of Queensland; Brisbane, QLD,
- 16 4072; Australia
- 17 6 Australian Institute for Bioengineering and Nanotechnology; The University
- 18 of Queensland; St Lucia, QLD, 4072; Australia
- 19
- 20 + These authors contributed equally
- 21 \* Correspondence: <u>a.freydenzon@uq.edu.au</u>

### 22 Author emails

- 23 Anna Freydenzon: <u>a.freydenzon@uq.edu.au</u>
- 24 Shivangi Wani: <u>s.wani@uq.edu.au</u>
- 25 Vanda Bharti: <u>v.bharti@uq.edu.au</u>
- 26 Leanne M. Wallace: <u>l.wallace@uq.edu.au</u>
- 27 Anjali K. Henders: <u>a.henders@uq.edu.au</u>
- 28 Pamela A. McCombe: pamela.mccombe@uq.edu.au
- 29 Robert D. Henderson: <u>Robert.Henderson@health.qld.gov.au</u>
- 30 Frederik J. Steyn: <u>f.steyn@uq.edu.au</u>
- 31 Naomi R. Wray: <u>naomi.wray@uq.edu.au</u>
- 32 Shyuan T. Ngo: <u>s.ngo@uq.edu.au</u>

### 33 Abstract

**Background**: Amyotrophic lateral sclerosis (ALS), the most predominant form of Motor Neuron Disease (MND), is a progressive and fatal neurodegenerative condition that spreads throughout the neuromotor system by afflicting upper and lower motor neurons. Lower motor neurons project from the central nervous system and innervate muscle fibres at motor endplates, which degrade over the course of the disease leading to muscle weakness. The direction of neurodegeration from or to the point of neuromuscular junctions and the role of muscle itself in pathogenesis has continued to be a topic of debate in ALS research.

41 **Methods**: To assess the variation in gene expression between affected and nonaffected 42 muscle tissue that might lead to this local degeneration of motor units, we generated RNA-43 seq skeletal muscle transcriptomes from 28 MND cases and 18 healthy controls and 44 conducted differential expression analyses on gene-level counts, as well as an isoform 45 switching analysis on isoform-level counts.

46 Results: We identified 52 differentially-expressed genes (Benjamini-Hochberg-adjusted 47 p < 0.05) within this comparison, including 38 protein coding, 9 long non-coding RNA, and 48 5 pseudogenes. Of protein-coding genes, 31 were upregulated in cases including with notable genes including the collagenic COL25A1 ( $p = 3.1 \times 10^{-10}$ ), SAA1 which is released 49 50 in response to tissue injury ( $p = 3.6 \times 10^{-5}$ ) as well as others of the SAA family, and the 51 actin-encoding ACTC1 ( $p = 2.3 \times 10^{-5}$ ). Additionally, we identified 17 genes which 52 exhibited a functional isoform switch with likely functional consequences between cases and 53 controls.

54 Conclusions: Our analyses provide evidence of increased tissue generation in MND cases,
55 which likely serve to compensate for the degeneration of motor units and skeletal muscle.

### 56 Keywords

Amyotrophic lateral sclerosis, ALS, motor neurone disease, transcriptomics, RNA-seq,
differential expression, alternative splicing

### 59 Background

60 Motor neuron disease (MND) is a group of several similar neurodegenerative disorders with 61 highly variable patterns of onset, progression, and symptomology. Amyotrophic lateral 62 sclerosis (ALS), the most predominant motor neuron disease, is identified as featuring both 63 upper and lower motor neuron loss. There is active discussion as to whether MND operates 64 as a 'dying forward' phenomenon where initial cell death occurs in the cortical motor 65 neurons and extends down into the corticospinal projections (1), or a 'dying back' 66 phenomenon where neuromuscular junctions (NMJs) are the first to suffer failure and the 67 pathology proceeds up the axon back into the body of the motor neuron (2). Nevertheless, the 68 progressive loss of upper and lower motor neurons results in the presentation of clinical

features including spasticity and brisk reflexes, and muscle weakness and wasting across multiple body regions (3). In MND, muscle weakness and wasting occurs in response to the dismantling of neuromuscular junctions (NMJs) and axonal retraction that ultimately results in the denervation of skeletal muscle and subsequent die-off (4). Compensatory mechanisms can be seen in surviving motor units; axon terminals undergo sprouting to markedly increase reinnervation of skeletal muscle, and this occurs in parallel with abnormally fast firing (5).

75 MND is a highly polygenic disease consisting of over 20 known associated genes, although 76 only ~10% of patients have familial history associated with mutations of large effect (4). One 77 functional mechanism implicated by MND-associated genes is disturbance in RNA 78 metabolism, which has contributed to an increasing research focus exploring transcriptomic 79 machinery (6). One of the most notable genes is TDP-43, which undergoes substantial 80 posttranslational modification and aggregation in both MND and frontotemporal dementia 81 (7), leading to targeted RNA instability in its overexpression that results in consequences for 82 ribosome biogenesis and oxidative phosphorylation pathways (8). Similarly, FUS is involved 83 in transcriptional regulation through binding to RNA targets to regulate splicing and the 84 removal of minor introns (9). Recent transcriptome-wide studies have been conducted on a 85 variety of different tissues and models to find aberrant differential gene expression reflected 86 in all tested tissue types, including but not limited to the postmortem motor cortex (10), 87 patient whole blood (11), motor neurons from stem-cell derived spinal motor axons (12), and 88 spinal cords from the recently generated PFN1 mouse model (13). Here, we report a whole 89 transcriptome analysis of skeletal muscle tissue from MND patients, and describe the 90 compensatory mechanisms invoked within MND-afflicted muscle tissue in response to 91 denervation and local cell death.

### 92 Methods

### 93 Patient recruitment

94 Patient recruitment and muscle biopsies were undertaken as described by Steyn et al. 2020 95 (14). Briefly, MND patients who met the revised El-Escorial criteria for ALS (15) at the time 96 of diagnosis were enrolled from the Royal Brisbane and Women's Hospital MND clinic for 97 the collection of skeletal muscle biopsies, along with healthy controls in the form of relatives, 98 friends or community volunteers. For all participants, exclusion criteria were history of a 99 metabolic condition (e.g. Hashimoto's disease) and diabetes mellitus. Participants involved in 100 the study are described in Table S1. Muscle biopsies (~200mg) were collected from the 101 vastus lateralis from one leg (the least affected leg for MND participants) using a hollow 102 Bergstrom biopsy needle modified for suction. Samples were placed in Dulbecco's Modified 103 EaglMedium/Ham's F-12 with 0.5% gentamicin for transport to the laboratory. A portion 104 (~50-100mg) of muscle tissue was divided from the primary biopsy, washed three times with 105 room temperature phosphate buffered saline, frozen on dry ice, and stored at -80 degrees 106 Celsius.

### 107 RNA sequencing

108 RNA sequencing was performed on MND and healthy controls for both blood and muscle 109 samples (36 overlapping; 23 cases, 13 controls). RNAseq was performed first on an initial 110 batch with all blood and muscle samples, followed by the same muscle samples being re-run 111 once (split across two additional batches) to increase total sequencing reads.

112 Muscle

113 Muscle samples passing QC were contributed by 17 healthy controls and 28 MND cases.

Total RNA was extracted from the muscle tissue using a standard Trizol-chloroform extraction method. Post extraction, the total RNA was quantitated using the Epoch microplate spectrophotometer followed by quality assessment on the Agilent Bioanalyzer using the RNA Nano kit. On average the samples yielded 7.4 micrograms of total RNA with an average RNA Integrity Number (RIN) of 8.2.

119 One microgram of DNAse1 treated total RNA was then used to prepare libraries for 120 sequencing. The libraries were prepared using Illumina's Truseq stranded total RNA library 121 prep gold kit in conjunction with the TruSeq RNA UD indexes. The libraries were then 122 equimolar pooled and paired end sequencing was carried out on HiSeq 4000 system.

123 **Blood** 

Blood samples passing QC were contributed to by 13 healthy controls and 24 MND cases. Approximately 2.5mL of whole blood was collected in PAXgene Blood RNA tubes. Total RNA was extracted from these tubes using the PAXgene Blood RNA kit from Qiagen. Post extraction, the total RNA was quantitated using the Nanodrop spectrophotometer followed by quality assessment on the Agilent Bioanalyzer using the RNA Nano kit. On average the samples yielded 4.8 micrograms of total RNA with an average RNA Integrity Number (RIN) of 8.2.

131 500ng of DNAse1 treated total RNA was then used to prepare libraries for sequencing. The 132 libraries were prepared using Illumina Truseq stranded total RNA library prep gold kit in 133 conjunction with the TruSeq RNA UD indexes. The libraries were then equimolar pooled and 134 paired end sequencing was carried out on HiSeq 4000 system.

135 Read processing

136 Initial QC and read trimming was undertaken using fastp (16), setting a threshold of 1 to pass

through all non-empty reads (aberrant reads being filtered in the alignment step). By default,
fastp conducts automatic adapter trimming by overlapping read pairs, as well as N-based
qualify filtering and polyG tail trimming.

Trimming reads were mapped to the GENCODE v32-indexed genome through STAR 2.7.3 (17) with non-default parameters suggested by the STAR 2.7.0 manual for ENCODE alignment. These parameters specify that splices are only recognized if they fall over indexed, known splice junctions, sets a maximum number of mismatches to be read length\* 0.04, limits genomic distance between read mates to 1,000,000 and sets a minimum intron length of 20bp.

146 The STAR-generated genome alignments were then quantified to gene meta-features through 147 Rsubread featurecounts (18), with the parameter requiring both pairs to be mapped. Samples 148 with alignment counts of < 20,000,000 across summed technical replicates were 149 consequently filtered out of the analysis (4 blood, 1 muscle).

150 In addition, Salmon 1.0 (19) was run in quasi-mapping mode to the GENCODE v32 151 transcriptome (indexed over k-mer length 17). This was done to verify signals detected in 152 STAR and act as a definitive source of transcripts as compared to the finer STAR genomic 153 alignment method. This was run with the non-default parameters of validateMappings, 154 seqBias, gcBias and useEM. This automatically estimates the library type (paired), runs in 155 selective alignment mode where it ranks potential alignment sites based on mapping score, 156 corrects for hexamer priming and GC biases and uses the expectation maximization (EM) 157 method for abundance estimates.

158 Tximport 1.20 (20) was used to aggregate the Salmon transcript counts across samples to159 acquire both the summarized gene counts for the analysis complimentary to STAR, as well as

160 the counts of the transcripts for differential isoform analyses.

### 161 Differential expression analyses

STAR-generated read counts were read into DESeq2 1.30.1 (21) to collapse replicates into a single measure, and to estimate size factors and dispersion factors. Genes with  $\geq$  3 samples with normalized counts  $\leq$  5 were pruned from the individual blood and muscle sets. The resulting subset of genes were then run through DESeq2's negative binomial GLM with a Wald significance test, increasing maximum iterations to 5,000.

167 The muscle and blood GLMs were fitted with MND as the condition and age and sex as

168 covariates. Additionally, a binary variable indicating whether the samples were replicated

across the second or third batch was added to the muscle model. These preliminary models

170 were designated as the 'base' models.

The variation in counts was visualized within the muscle and blood samples through a principal component analysis applied to the 500 genes with highest variance across all samples, as well as through plotting the relative log expression on both centered and noncentered counts. Two control muscle samples were consequently dropped from further analysis due to featuring highly irregular counts and variance.

The genomic inflation factor (GIF) for each analysis (blood and muscle) was calculated as the median of the  $\chi^2$  test statistic divided by the median of the  $\chi^2$  distribution with one degree of freedom (22). The GIF is a summary statistic that compares the distribution of test statistics against expectation under the null hypothesis of no association of gene expression with MND and has an expected value of 1 when confounding is absent from the data, under the assumption that at least 50% of tests represent truly null associations. The GIF of the muscle models was found to be high, and as such a surrogate variable analysis (SVA) was

conducted individually for blood and muscle using the R sva 3.38 package (23). SVA analysis estimates the probability of each gene being an empirical control gene (i.e., not associated with MND) through an iterative re-weighted least squares regression and captures variation outside of a specified model with known covariates. In this case, the SVA was conducted with MND status as the only covariate to preserve in the non-null model. This function also generated a suggested number of SVs to use in differential expression analysis through a permutation procedure.

190 Genes with Benjamini-Hochberg-adjusted p-values falling under the significance threshold of 191 0.05 were deemed as transcriptome-wide significant and were taken forward for further 192 enrichment analyses. The union of genes significant to Salmon and STAR models formed the 193 gene list entered gprofiler 0.2 (24) gene ontology enrichment and the STRING 11.0 (25) 194 protein-protein interaction network tools using default settings. The *p*-values returned by this 195 enrichment analysis are adjusted for multiple testing by gprofiler2's default gSCS algorithm. 196 Additionally, a supplementary analysis was conducted with the Revised Amyotrophic Lateral 197 Sclerosis Functional Rating Scale (ALSFRS-R) (26) lower limb subscore as the outcome, 198 adjusting for age, sex and the estimated surrogate variables. This subscore combined scored 199 answers for questions relating to the ability to walk and the ability to climb stairs, with lower 200 values reflecting decreased ability.

Finally, the isoform-level length-scaled transcript counts generated by Salmon for the muscle data were analyzed through the IsoformSwitchAnalyzeR (27) 1.12 library in R. This package implements visualization and annotation functions on top of a DEXSeq, which currently implements DESeq2's normalization and estimation approaches to iteratively compare the number of transcripts of a given exon compared to the rest of that gene (28) but in this case for isoforms. Isoforms were annotated to exons through the Gencode v32 primary assembly.

207 Following default prefiltering, isoforms were tested for differential usage using MND status 208 as its condition, adjusted for age, sex and batch effect, then analyzed for alternative splicing 209 as well as predicted the open reading frame (ORF) of each isoform of significantly switched 210 genes. IsoFormSwitchAnalyzer implements multiple functions for the export of all isoform 211 sequences for genes with a significant switch, and the import of the results from external 212 annotation databases utilizing these. The databases were CPAT (using the suggested human 213 coding threshold of 0.364) (29) for coding potential, SignalP (30) for predicting signal 214 peptide sites, IUPred2A (31) to predict intrinsically disordered regions (IDRs) and Pfam (32) 215 to predict protein domains.

### 216 **Results**

217 Quality control of the RNAseq reads for each sample using PHRED scores indicated the 218 quality was high, with the main batch containing mean scores at each base pair across reads 219 and samples of > 30. However, the samples demonstrated some form of degradation 220 (potentially from long-term storage), particularly for blood. Mean genome alignment over all 221 blood and muscle samples through STAR was 54.4% and 87.6% respectively, while the 222 proportion of those which were assigned to exons were 29.8% and 58.2% respectively. For 223 Salmon, a mean of 74.1% of reads mapped to the transcriptome and were successfully 224 assigned a feature in muscle, whereas this number was only 40% in blood. The proportions 225 of the reads successfully assigned to a feature are plotted in Figure S1 for STAR and Figure 226 S2 for Salmon.

A principal component analysis of the transcript levels revealed a differing pattern of variation between the blood and muscle analyses (**Figure 1**). The second principal component of both blood and muscle (explaining 7.2% and 8.4% of variance in gene expression, respectively), captured sex differences (correlation r = 0.90 with  $p = 4.9 \times$ 

 $10^{-14}$  for blood, and r = -0.89 with  $p = 2.6 \times 10^{-16}$  for muscle). The first principal 231 232 component in muscle (explaining 22.3% of expression variance) captured differences 233 between cases and controls. The second principal component in muscle is significantly 234 correlated with the lower limb subscore of the ALSFRS-R when estimating the PCA in case 235 counts only (r = 0.46, p = 0.014). The relative log expression of the counts (centered and 236 non-centered) passing QC is displayed within **Figure S3**. Similar observations with regards 237 to the principal components and correlations apply to the counts as generated through STAR 238 (Figure S4).

239 Testing for case-control differences in gene-expression levels in muscle while correcting for 240 age, sex and replicate batch effect identified additional confounding within the data. The 241 genomic inflation factor (GIF) of Salmon and STAR were 2.53 and 3.47 respectively, with 242 3258 and 6874 transcriptome-wide significant genes detected under the adjusted p-value of 243 0.05 (Figure S5). This was corrected with the addition of an automatically determined 244 number of surrogate variables to each model as calculated by permutation procedure. With 245 this correction the GIF falls to 1.18 and 1.13, with 38 and 26 significant genes for Salmon 246 and STAR-aligned data respectively. For the blood transcriptome analysis, such inflation was 247 not an issue (a GIF of 0.85 and 1.01 in Salmon and STAR respectively, with two significant 248 genes each) and as such no SVs were added to the model.

Of the 38 and 26 genes detected by Salmon and STAR respectively, there was an intersection of 12 (**Table 1**) with the same direction of fold change for both methods. The complete list of transcriptome-wide genes for each model in each tissue type as well as their test statistics can be found in individual tabs of **Table S2**. Of the 52 genes identified by either Salmon and STAR models, 9 were long non-coding RNAs and 5 were pseudogenes. Of the 38 proteincoding genes, 7 had lower expression and 31 had higher expression in MND cases versus

controls. As one of these genes, AHRR, is a known smoking biomarker in blood (33) we conducted an additional iteration of the 'base' model for muscle with the addition of eversmoked status (23 never, 22 ever). MND status was found to be significantly associated with AHRR count in the STAR model (log<sub>2</sub>FC = 1.98, p = 0.0085), whereas smoking history was not (log<sub>2</sub>FC -0.11, p = 0.88).

260 A gene ontology enrichment analysis conducted on the results of each method (**Table 2**) 261 revealed shared enrichment for the GO biological processes term of acute phase response  $(p = 1.4 \times 10^{-3} \text{ and } p = 5.5 \times 10^{-4} \text{ for Salmon and STAR respectively})$ , attributable to the 262 263 components of serum amyloid A within the set. Other notable terms enriched in the significant results for Salmon were cardiac muscle tissue morphogenesis ( $p = 4.4 \times 10^{-3}$ ), 264 positive regulation of synapse assembly  $(p = 4.7 \times 10^{-3})$ , and tissue migration  $(p = 7.3 \times 10^{-3})$ 265  $10^{-3}$ ). For STAR, notable terms were skeletal muscle tissue growth ( $p = 9.7 \times 10^{-3}$ ), 266 axonogenesis involved in innervation ( $p = 8.4 \times 10^{-3}$ ) and neutrophil clearance ( $p = 7.0 \times 10^{-3}$ ) 267  $10^{-3}$ ). However, these terms test as enriched due to having one or two significant genes 268 269 detected from a small pool of other genes in the global set annotated with the term. The 270 unified set of differentially expressed proteins between STAR and Salmon in muscle was 271 identified to have significantly more interactions (9) than expected (4, p = 0.01) according to 272 the STRING pathway analysis, indicating a likely biological relation if not interaction 273 between them (Figure S6).

Within the blood sample, the *ODZ1* homolog pseudogene *AL0087071*, notably found on the X-chromosome, was the only gene differentially expressed by both Salmon and STAR methods (respective log<sub>2</sub>FCs of 3.14 and 3.07, with a  $p = 1.9 \times 10^{-6}$  and  $p = 3.5 \times 10^{-6}$ , **Table S3**). *EDH2* was not detected by the STAR aligner though was significantly expressed in Salmon (log<sub>2</sub>FC of -1.75;  $p = 7.0 \times 10^{-7}$ ) and the expression of *FSD1L* was only found

#### 279 significant in STAR (log<sub>2</sub>FC of 0.57; $p = 2.0 \times 10^{-6}$ ).



additional surrogate variables (as the number automatically suggested by the function).

285 A total of 17 genes were identified with isoform switches within the muscle sample falling 286 underneath the FDR-adjusted p-value (q-value) of 0.05 and having predicted functional 287 consequences to the expressed protein. The list of features, their direction of consequence and 288 the genes falling under each is listed in **Table S5**. The individual per-isoform tests for each 289 gene are available in **Table S6**. No significant (FDR < 0.05) directionality of functional 290 consequences of these isoform differences was observed for any genomic feature, although 291 there was a slight increase in switching to longer transcripts (8:6 longer vs. shorter switches) 292 and an increase in exon number gain (6:3 gain vs. loss of exon count).

293 From the isoform switches with functional consequences, only SAA2 was represented within 294 our main gene-level analysis. SAA2 featured an increase of its ENST00000256733 isoform fraction by 24% ( $q = 5.74 \times 10^{-11}$ ) correlated with a decrease of its ENST00000528349 295 isoform fraction by 25% ( $q = 9.84 \times 10^{-11}$ ). The resulting functional consequence was an 296 297 overall decrease in transcript length by a shortened 3' UTR and the reduction of intron 3-4 298 from 3090 to 394 bp, increasing its predicted coding potential (Figure 2). Two other isoform 299 switches with predicted gain in coding potential are PLCE1 (Figure S7) and SAMD4A 300 (Figure S8). PIP5K1B (Figure S9) and MYH3 (Figure S10) also have gain in domains 301 which indicate that the isoform with increased expression encodes the more complete version 302 of the protein.

### 303 Discussion

The majority of studies on muscle changes associated with MND have been performed in mice (34,35) or iPSC-derived cell-culture (36). To our knowledge, our study is one of the first investigations into the transcriptomic machinery in human MND muscle tissue and provides a substantial increase in the number of individuals examined. We identify 38 protein-coding genes differentially expressed between MND cases and controls with 31 of these being upregulated in cases. Muscle biopsies were sampled from the healthier leg in MND cases.

311 Serum amyloid A transcripts (specifically SAA1, SAA2 and the SAA2-SAA4 readthrough, 312 contiguously located on chromosome 11) were highly expressed in MND patients. SAA is 313 persistently elevated in other chronic inflammatory diseases and a reliable indicator of 314 inflammation due to an up-to 1000-fold increase in plasma levels during acute phase 315 responses (37). In a heightened response, SAA most often becomes associated with the lipid 316 surface of high-density lipoproteins (HDLs), possibly as a stabilized hub to interact with 317 other cellular components (38). In its association with HDL cholesterol, SAA is indicated to 318 be involved in stimulating the inflammatory response within the innate immune system (39). 319 Other acute phase proteins such as C-reactive protein and CD14 have been detected as 320 elevated in MND sera, and increased levels of these are reported to be associated with disease 321 progression and mortality rate (40). In addition to the aforementioned acute phase proteins, 322 several components of the complement system including C3 (41), C4 (42), and C5a/C5b-9 323 (43) have been reported to be higher in the whole blood, serum or plasma of ALS cases to 324 controls in previous studies. As such, it may be of value in the future to investigate local 325 accumulation of SAA as a biomarker for disease progression and as a representation of the 326 overall inflammatory response.

327 Several genes associated with tissue generation are detected as positively expressed in cases. 328 *FST* (follistatin) is a receptor agonist which binds to other transforming growth factor- $\beta$ 329 ligands, including myostatin and activin-A which would otherwise limit muscle mass without 330 inhibition (44). Additionally, FST has an antagonistic effect on several bone morphogenic 331 proteins, of which it forms a complex with and alters signaling to induce muscle hypertrophy 332 while reducing atrophy (45). MYH3, a myosin heavy-chain encoding gene primarily 333 expressed embryonically, was not captured by the gene-based analyses; however, the 334 differential isoform expression analysis indicated a heightened expression of its most 335 complete isoform within MND cases. This is of particular interest as MYH3 has been 336 indicated as a valid and robust biomarker for skeletal muscle tissue regeneration across all 337 ages in other muscle-wasting diseases such as Duchenne muscular dystrophy (46). Muscle 338 tissue does not exist in the body solely as actin filaments, but bundled within a complex net 339 of connective tissue and infiltrating immune cells (47). Other genes instrumental in tissue 340 development and differentiation found expressed higher in cases are the keratin KRT80 (48), 341 the actin-binding protein encoding SHROOM3 which is utilized for epithelial folding in 342 neural tube closure (49), and filamentous actin-binding ectodermal-neural cortex 1 ENC1 343 (50).

344 Several transcripts found over-expressed in MND cases are not principally expressed by 345 skeletal muscle tissues in adulthood. For instance, ACTC1 was found to be significantly 346 upregulated but not ACTA1. ACTC1 encodes the  $\alpha$ -cardiac muscle actin which constitutes 347 < 5% of skeletal muscle by adulthood, whereas ACTA1 encodes the almost-identical 348 predominant muscular isoform  $\alpha$ -skeletal muscle actin (51). Within a small case study of 7 349 congenital myopathy patients with a complete lack of  $\alpha$ -skeletal muscle actin,  $\alpha$ -cardiac actin 350 was shown to constitute muscle tissues and the highest amount correlated to the participant 351 with the best muscular function (52). However, as ACTA1 has been previously identified to

be increased as a function of compensatory hypertrophy in a small real-time PCR study of 5 ALS patients, a larger sample size may capture the increased expression of both it and *ACTC1* (53). *ANKRD1/CARP* is the ankryn repeat domain most present in cardiac tissue and is shown to be over-expressed within MND muscle compared to controls unlike its skeletal muscle paralog, *ANKRD2/ARPP*. However, *ANKRD1* expression has also been noted to increase in skeletal muscle with denervation-induced atrophy in murine models (54).

358 The expression of extracellular matrix components and collagens COL19A1 and COL25A1 359 was also found to be increased with muscle tissue genes such as ACTC1. COL25A1, encoding 360 the collagen type XXV alpha 1 chain, is a known Alzheimer's risk gene (55) for its role in 361 assisting the formation of characteristic senile plaques when over-expressed in the brain (56). 362 The cleavage of COL25A1 creates the proteolytic CLAC (collagenous Alzheimer amyloid 363 plaque component), and as such has the alias of CLAC-P (precursor) (57). Collagen XXV is 364 expressed primarily in skeletal muscle during development, acting as a required factor in 365 myofiber fusion from myoblasts in early myogenesis (58). COL25A1-KO mice nearly 366 completely failed to innervate skeletal muscle tissue during development by not being able to 367 elongate and branch motor axon bundles, indicating it as a required component to initial 368 intramuscular motor innervation (59). Collagen XIX structures part of the basement 369 membranes, and is present in a host of different tissues including skeletal muscle, axons, 370 epithelia and brain intraneurons (60). As collagens are vital in the production of functional 371 skeletal muscle tissue, their increased expression in MND further supports the evidence of 372 attempted muscle repair as a compensatory response. Higher COL19A1 expression levels in 373 MND muscle biopsies have already been linked to faster progression of the disease (61).

A few other highly upregulated genes of note include some that are influenced by the multiple upregulated transcription factors in the set (*SP1* and *MYCL*). The increased

376 expression of TDO2 and AHRR may indicate the presence of prior AHR upregulation, which 377 has been indicated to be invoked in neural cell proliferation (62). Following AHRR and the 378 aforementioned SAA1, tryptophan catabolism enzyme TDO2 has the largest positive fold-379 change in expression. TDO2 is ordinarily expressed in the liver as a tryptophan regulator and 380 is also known as an oncogene commonly expressed in most cancers (63). While the products 381 of the catabolic kynurenine pathway include metabolites used for neurotransmission and 382 immune regulation, TDO2 depletes free tryptophan used for proliferation of T-cells and 383 produces kynurenine that inhibits the proliferation of effector T lymphocytes and promoting 384 regulatory T-cell differentiation, and activates the transcription factor AHR (64). The 385 kynurenine pathway itself produces metabolites that influence energy homeostasis in skeletal 386 muscle and other tissues, and kynurenic acid (a product of the pathway) increases energy 387 utilization while also acting as an AHR ligand (65).

### 388 Conclusions

In summary, we identify 52 genes whose expression in muscle is significantly associated with MND cases versus controls, with the majority showing increased expression in cases. These genes encode vital structural components of muscle, particularly in regenerative or early developmental processes. This provides novel insight into the repair mechanisms triggered in the presence of neurodegeneration and muscle wasting in MND, as well as the chronic inflammation within these tissues as evidenced by expression of acute-phase proteins.

### 396 Abbreviations

397 ALS-FRS-R: Revised Amyotrophic Lateral Sclerosis Functional Rating Scale

- *ALS*: Amyotrophic lateral sclerosis
- *EM*: Expectation maximalization
- *GIF*: Surrogate variable analysis
- *lncRNA*: Long non-coding RNA
- *MND*: Motor neurone disease
- *NMJ*: Neuromuscular junction
- **ORF**: Open reading frame
- *PC*: Protein coding
- *PCA*: Principal component analysis
- *PP*: Processed pseudogene
- *RIN*: RNA integrity number
- *TUP*: Transcribed unprocessed pseudogene.
- *UP*: Unprocessed pseudogene

# **Declarations**

- 412 Ethics approval and content to participate
- 413 All work performed in this study was approved by the Royal Brisbane and Women's Hospital
- and University of Queensland human research ethics committees. All participants provided
- 415 written informed consent.

### 416 Consent for publication

- 417 Not applicable.
- 418 Availability of data and materials
- 419 The data that support the findings of this study are available on request from the
- 420 corresponding author. The raw transcript data are not publicly available due to ethical
- 421 restrictions; however, gene and transcript counts have been made available. The datasets
- 422 generated during and/or analysed during the current study are available in the University of
- 423 Queensland data collection repository, <u>https://doi.org/10.48610/b722f1f</u>.
- 424 Competing interests
- 425 The authors declare that they have no competing interests.
- 426 Funding
- 427 This research was supported through funding from the Scott Sullivan MND Research
- 428 Fellowship to S.T.N. (2015-2020; MND and Me Foundation and RBWH Foundation),
- 429 FightMND Mid-Career Fellowship (to S.T.N.), MNDRA Charcot Grant (GIA 1701 to S.T.N.
- 430 and F.J.S.), the National Health and Medical Research Council Australia (1101085 to S.T.N.
- 431 and F.J.S., 1113400 & 1173790 to N.R.W.) and the Australian Research Council (Future
- 432 Fellowship 200100837 to A.F.M.).
- 433 Authors' contributions
- 434 A.F., A.F.M., and N.R.W. wrote the paper. A.F. conducted the analyses. A.F.M., N.R.W.,
- and S.T.N. conceptualized this work. S.W and V.B. processed the samples for sequencing.
- 436 L.M.W. and A.K.H. allocated laboratory resources and supervised sample processing. P.A.M.
- 437 and R.D.H. provided samples. S.T.N. and F.J.S. performed the muscle biopsies. All authors
- 438 read and approved the final manuscript.

## 439 Acknowledgements

- 440 The authors thank all patients and participants who provided biological samples for use in
- this research.

## 442 **References**

- Cappello V, Francolini M. Neuromuscular Junction Dismantling in Amyotrophic Lateral
   Sclerosis. IJMS. 2017 Oct 3;18(10):2092.
- Manzano R, Toivonen JM, Moreno-Martínez L, Torre M, Moreno-García L, López-Royo T,
   et al. What skeletal muscle has to say in amyotrophic lateral sclerosis: Implications for
   therapy. Br J Pharmacol. 2021 Mar;178(6):1279–97.
- 448 3. Morris J. Amyotrophic Lateral Sclerosis (ALS) and Related Motor Neuron Diseases: An
  449 Overview. The Neurodiagnostic Journal. 2015 Sep;55(3):180–94.
- 4. Masrori P, Van Damme P. Amyotrophic lateral sclerosis: a clinical review. Eur J Neurol.
   2020 Oct;27(10):1918–29.
- 452 5. Weddell T, Bashford J, Wickham A, Iniesta R, Chen M, Zhou P, et al. First-recruited motor
  453 units adopt a faster phenotype in amyotrophic lateral sclerosis. The Journal of
  454 Physiology [Internet]. 2021 Jul 14 [cited 2021 Jul 20];n/a(n/a). Available from:
  455 https://doi.org/10.1113/JP281310
- 456 6. Taylor JP, Brown RH, Cleveland DW. Decoding ALS: from genes to mechanism. Nature.
  457 2016 Nov;539(7628):197-206.
- 458 7. Xue YC, Ng CS, Xiang P, Liu H, Zhang K, Mohamud Y, et al. Dysregulation of RNA-Binding
  459 Proteins in Amyotrophic Lateral Sclerosis. Front Mol Neurosci. 2020 May 29;13:78.
- 460 8. Tank EM, Figueroa-Romero C, Hinder LM, Bedi K, Archbold HC, Li X, et al. Abnormal RNA
  461 stability in amyotrophic lateral sclerosis. Nat Commun. 2018 Dec;9(1):2845.
- 462 9. Butti Z, Patten SA. RNA Dysregulation in Amyotrophic Lateral Sclerosis. Front Genet.
  463 2019 Jan 22;9:712.
- 464 10. Dols-Icardo O, Montal V, Sirisi S, López-Pernas G, Cervera-Carles L, Querol-Vilaseca M, et
  465 al. Motor cortex transcriptome reveals microglial key events in amyotrophic lateral
  466 sclerosis. Neurol Neuroimmunol Neuroinflamm. 2020 Sep;7(5):e829.
- 467 11. van Rheenen W, Diekstra FP, Harschnitz O, Westeneng HJ, van Eijk KR, Saris CGJ, et al.
  468 Whole blood transcriptome analysis in amyotrophic lateral sclerosis: A biomarker study.
  469 Raoul C, editor. PLoS ONE. 2018 Jun 25;13(6):e0198874.
- 470 12. Nijssen J, Aguila J, Hoogstraaten R, Kee N, Hedlund E. Axon-Seq Decodes the Motor
  471 Axon Transcriptome and Its Modulation in Response to ALS. Stem Cell Reports. 2018
  472 Dec;11(6):1565-78.
- 473 13. Barham C, Fil D, Byrum SD, Rahmatallah Y, Glazko G, Kiaei M. RNA-Seq Analysis of Spinal
  474 Cord Tissues from hPFN1G118V Transgenic Mouse Model of ALS at Pre-symptomatic
  475 and End-Stages of Disease. Scientific Reports. 2018 Sep 13;8(1):13737.

476 14. Steyn FJ, Li R, Kirk SE, Tefera TW, Xie TY, Tracey TJ, et al. Altered skeletal muscle glucose 477 fatty acid flux in amyotrophic lateral sclerosis. Brain Communications. 2020 Sep

- 478 24;fcaa154.
- 479 15. Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: Revised criteria for the
  480 diagnosis of amyotrophic lateral sclerosis. null. 2000 Jan 1;1(5):293–9.
- 481 16. Chen S, Zhou Y, Chen Y, Gu J. fastp: an ultra-fast all-in-one FASTQ preprocessor.
  482 Bioinformatics. 2018 Sep 1;34(17):i884–90.
- 17. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast
  universal RNA-seq aligner. Bioinformatics. 2013 Jan;29(1):15–21.
- Liao Y, Smyth GK, Shi W. The R package Rsubread is easier, faster, cheaper and better
  for alignment and quantification of RNA sequencing reads. Nucleic Acids Research. 2019
  May 7;47(8):e47–e47.
- 488 19. Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C. Salmon provides fast and bias-aware
   489 quantification of transcript expression. Nat Methods. 2017 Apr;14(4):417–9.
- 490 20. Soneson C, Love MI, Robinson MD. Differential analyses for RNA-seq: transcript-level
  491 estimates improve gene-level inferences. F1000Res. 2015;4:1521.
- 492 21. Anders S, Huber W. Differential expression of RNA-Seq data at the gene level the
  493 DESeq package. :24.
- 494 22. Devlin B, Roeder K. Genomic Control for Association Studies. Biometrics.
  495 1999;55(4):997–1004.
- 496 23. Leek JT, Johnson WE, Parker HS, Jaffe AE, Storey JD. The sva package for removing batch
  497 effects and other unwanted variation in high-throughput experiments. Bioinformatics.
  498 2012 Mar 15;28(6):882–3.
- 499 24. Raudvere U, Kolberg L, Kuzmin I, Arak T, Adler P, Peterson H, et al. g:Profiler: a web
  500 server for functional enrichment analysis and conversions of gene lists (2019 update).
  501 Nucleic Acids Research. 2019 Jul 2;47(W1):W191–8.
- 502 25. Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11:
  503 protein-protein association networks with increased coverage, supporting functional
  504 discovery in genome-wide experimental datasets. Nucleic Acids Research. 2019 Jan
  505 8;47(D1):D607-13.
- 26. Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: a
  revised ALS functional rating scale that incorporates assessments of respiratory
  function. Journal of the Neurological Sciences. 1999 Oct 31;169(1):13–21.
- 509 27. Vitting-Seerup K, Sandelin A. IsoformSwitchAnalyzeR: analysis of changes in genome510 wide patterns of alternative splicing and its functional consequences. Bioinformatics.
  511 2019 Nov 1;35(21):4469–71.

- 512 28. Anders S, Reyes A, Huber W. Detecting differential usage of exons from RNA-seq data.
  513 Genome Research. 2012 Oct 1;22(10):2008–17.
- 29. Wang L, Park HJ, Dasari S, Wang S, Kocher JP, Li W. CPAT: Coding-Potential Assessment
  Tool using an alignment-free logistic regression model. Nucleic Acids Research. 2013 Apr
  1;41(6):e74–e74.
- 30. Almagro Armenteros JJ, Tsirigos KD, Sønderby CK, Petersen TN, Winther O, Brunak S, et
  al. SignalP 5.0 improves signal peptide predictions using deep neural networks. Nature
  Biotechnology. 2019 Apr 1;37(4):420–3.
- 520 31. Mészáros B, Erdős G, Dosztányi Z. IUPred2A: context-dependent prediction of protein
  521 disorder as a function of redox state and protein binding. Nucleic Acids Research. 2018
  522 Jul 2;46(W1):W329–37.
- 32. Mistry J, Chuguransky S, Williams L, Qureshi M, Salazar GA, Sonnhammer ELL, et al.
  Pfam: The protein families database in 2021. Nucleic Acids Research. 2021 Jan
  8;49(D1):D412–9.
- 33. Reynolds LM, Wan M, Ding J, Taylor JR, Lohman K, Su D, et al. DNA Methylation of the
  Aryl Hydrocarbon Receptor Repressor Associations With Cigarette Smoking and
  Subclinical Atherosclerosis. Circulation: Cardiovascular Genetics. 2015 Oct 1;8(5):707–
  16.
- 530 34. Ehmsen JT, Kawaguchi R, Mi R, Coppola G, Höke A. Longitudinal RNA-Seq analysis of
  531 acute and chronic neurogenic skeletal muscle atrophy. Scientific Data. 2019 Sep
  532 24;6(1):179.
- 533 35. Gonzalez de Aguilar JL, Niederhauser-Wiederkehr C, Halter B, De Tapia M, Di Scala F,
  534 Demougin P, et al. Gene profiling of skeletal muscle in an amyotrophic lateral sclerosis
  535 mouse model. Physiological Genomics. 2008 Jan 1;32(2):207–18.
- 36. Lynch EM, Robertson S, FitzGibbons C, Reilly M, Switalski C, Eckardt A, et al.
  Transcriptome analysis using patient iPSC-derived skeletal myocytes: Bet1L as a new
  molecule possibly linked to neuromuscular junction degeneration in ALS. Experimental
  Neurology. 2021 Nov 1;345:113815.
- 540 37. Ye RD, Sun L. Emerging functions of serum amyloid A in inflammation. Journal of
  541 Leukocyte Biology. 2015 Dec;98(6):923-9.
- 38. Webb NR. High-Density Lipoproteins and Serum Amyloid A (SAA). Curr Atheroscler Rep.
  2021 Feb;23(2):7.
- 39. Sack GH. Serum amyloid A a review. Mol Med. 2018 Dec;24(1):46.
- 40. Beers DR, Zhao W, Neal DW, Thonhoff JR, Thome AD, Faridar A, et al. Elevated acute
  phase proteins reflect peripheral inflammation and disease severity in patients with
  amyotrophic lateral sclerosis. Sci Rep. 2020 Dec;10(1):15295.

- 548 41. Chen X, Feng W, Huang R, Guo X, Chen Y, Zheng Z, et al. Evidence for peripheral immune
  549 activation in amyotrophic lateral sclerosis. Journal of the Neurological Sciences. 2014
  550 Dec 15;347(1):90–5.
- 42. Kjældgaard AL, Pilely K, Olsen KS, Øberg Lauritsen A, Wørlich Pedersen S, Svenstrup K, et
  al. Complement Profiles in Patients with Amyotrophic Lateral Sclerosis: A Prospective
  Observational Cohort Study. J Inflamm Res. 2021;14:1043–53.
- 43. Mantovani S, Gordon R, Macmaw JK, Pfluger CMM, Henderson RD, Noakes PG, et al.
  Elevation of the terminal complement activation products C5a and C5b-9 in ALS patient
  blood. J Neuroimmunol. 2014 Nov 15;276(1–2):213–8.
- 44. Lee SJ, Lee YS, Zimmers TA, Soleimani A, Matzuk MM, Tsuchida K, et al. Regulation of
  muscle mass by follistatin and activins. Mol Endocrinol. 2010/09/01 ed. 2010
  Oct;24(10):1998–2008.
- 45. Winbanks CE, Chen JL, Qian H, Liu Y, Bernardo BC, Beyer C, et al. The bone
  morphogenetic protein axis is a positive regulator of skeletal muscle mass. Journal of
  Cell Biology. 2013 Oct 21;203(2):345–57.
- 46. Guiraud S, Edwards B, Squire SE, Moir L, Berg A, Babbs A, et al. Embryonic myosin is a
  regeneration marker to monitor utrophin-based therapies for DMD. Human Molecular
  Genetics [Internet]. 2018 Oct 9 [cited 2022 Feb 24]; Available from:
  https://apadamia.gup.com/hmg/advance.article/doi/10.1002/hmg/ddv252/5124574
- 566 https://academic.oup.com/hmg/advance-article/doi/10.1093/hmg/ddy353/5124574
- 47. Mukund K, Subramaniam S. Skeletal muscle: A review of molecular structure and
  function, in health and disease. WIREs Systems Biology and Medicine. 2020 Jan
  1;12(1):e1462.
- 48. Li C, Liu X, Liu Y, Liu X, Wang R, Liao J, et al. Keratin 80 promotes migration and invasion
  of colorectal carcinoma by interacting with PRKDC via activating the AKT pathway. Cell
  Death Dis. 2018 Oct;9(10):1009.
- 49. Haigo SL, Hildebrand JD, Harland RM, Wallingford JB. Shroom Induces Apical
  Constriction and Is Required for Hingepoint Formation during Neural Tube Closure.
  Current Biology. 2003 Dec;13(24):2125–37.
- 576 50. Cui Y, Yang J, Bai Y, Li Q, Yao Y, Liu C, et al. ENC1 Facilitates Colorectal Carcinoma
  577 Tumorigenesis and Metastasis via JAK2/STAT5/AKT Axis-Mediated Epithelial
  578 Mesenchymal Transition and Stemness. Front Cell Dev Biol. 2021 Mar 16;9:616887.
- 579 51. Sztal TE, McKaige EA, Williams C, Ruparelia AA, Bryson-Richardson RJ. Genetic
  580 compensation triggered by actin mutation prevents the muscle damage caused by loss
  581 of actin protein. Stainier DYR, editor. PLoS Genet. 2018 Feb 8;14(2):e1007212.
- 52. Nowak KJ, Sewry CA, Navarro C, Squier W, Reina C, Ricoy JR, et al. Nemaline myopathy
   caused by absence of α-skeletal muscle actin. Ann Neurol. 2007 Feb;61(2):175–84.

584 53. Jensen L, Jørgensen LH, Bech RD, Frandsen U, Schrøder HD. Skeletal Muscle Remodelling
585 as a Function of Disease Progression in Amyotrophic Lateral Sclerosis. Biomed Res Int.
586 2016;2016:5930621.

- 587 54. Laure L, Suel L, Roudaut C, Bourg N, Ouali A, Bartoli M, et al. Cardiac ankyrin repeat
  588 protein is a marker of skeletal muscle pathological remodelling: Cardiac ankyrin repeat
  589 protein in muscle plasticity. FEBS Journal. 2009 Feb;276(3):669–84.
- 55. Forsell C, Björk BF, Lilius L, Axelman K, Fabre SF, Fratiglioni L, et al. Genetic association to
  the amyloid plaque associated protein gene COL25A1 in Alzheimer's disease. Neurobiol
  Aging. 2010 Mar;31(3):409–15.
- 593 56. Tong Y, Xu Y, Scearce-Levie K, Ptáček LJ, Fu YH. COL25A1 triggers and promotes 594 Alzheimer's disease-like pathology in vivo. Neurogenetics. 2010 Feb;11(1):41–52.
- 57. Hashimoto T, Fujii D, Naka Y, Kashiwagi-Hakozaki M, Matsuo Y, Matsuura Y, et al.
  Collagenous Alzheimer amyloid plaque component impacts on the compaction of amyloid-β plaques. acta neuropathol commun. 2020 Dec;8(1):212.
- 598 58. Gonçalves TJM, Boutillon F, Lefebvre S, Goffin V, Iwatsubo T, Wakabayashi T, et al.
  599 Collagen XXV promotes myoblast fusion during myogenic differentiation and muscle
  600 formation. Sci Rep. 2019 Dec;9(1):5878.
- 59. Tanaka T, Wakabayashi T, Oizumi H, Nishio S, Sato T, Harada A, et al. CLAC-P/Collagen
  Type XXV Is Required for the Intramuscular Innervation of Motoneurons during
  Neuromuscular Development. Journal of Neuroscience. 2014 Jan 22;34(4):1370–9.
- 604 60. Calvo AC, Moreno L, Moreno L, Toivonen JM, Manzano R, Molina N, et al. Type XIX
  605 collagen: a promising biomarker from the basement membranes. Neural Regen Res.
  606 2020 Jun;15(6):988–95.
- 607 61. Calvo AC, Cibreiro GA, Merino PT, Roy JF, Galiana A, Rufián AJ, et al. Collagen XIX Alpha 1
  608 Improves Prognosis in Amyotrophic Lateral Sclerosis. Aging and disease. 2019;10(2):278.
- 609 62. Juricek L, Coumoul X. The Aryl Hydrocarbon Receptor and the Nervous System. IJMS.
  610 2018 Aug 24;19(9):2504.
- 63. Hoffmann D, Dvorakova T, Stroobant V, Bouzin C, Daumerie A, Solvay M, et al.
  Tryptophan 2,3-Dioxygenase Expression Identified in Human Hepatocellular Carcinoma
  Cells and in Intratumoral Pericytes of Most Cancers. Cancer Immunol Res. 2020
- 614 Jan;8(1):19<del>-</del>31.
- 615 64. Opitz CA, Somarribas Patterson LF, Mohapatra SR, Dewi DL, Sadik A, Platten M, et al.
  616 The therapeutic potential of targeting tryptophan catabolism in cancer. Br J Cancer.
  617 2020 Jan 7;122(1):30–44.
- 618 65. Liu JJ, Movassat J, Portha B. Emerging role for kynurenines in metabolic pathologies.
  619 Current Opinion in Clinical Nutrition & Metabolic Care [Internet]. 2019;22(1). Available
  620 from: https://journals.lww.com/co-

### 621 clinicalnutrition/Fulltext/2019/01000/Emerging\_role\_for\_kynurenines\_in\_metabolic.15.

- 622 aspx
- 623

### 624 Figures





**Figure 1**. First two principal components of transcriptome log counts (regularized using Salmon)

627 consisting of the top 500 most variable genes for blood and muscle respectively. PC1 in muscle

628 captures variation between cases in sampled lower limb lower motor neurone scores (r = 0.40,

p = 0.041), though does not fully separate cases and controls. PC2 captures sex differences for both

630 tissue types (blood: r = 0.90,  $p = 4.9 \times 10^{-14}$ ; muscle: r = -0.89,  $p = 2.6 \times 10^{-16}$ ).

631 Ellipses added to visualize confidence between cases and controls.



634 Figure 2. Visualization of isoform expression in the transcriptome-wide significant gene SAA2. The 635 coloured plots at the top show three transcripts (detected via Salmon), annotated for their inclusion of 636 protein domains as well as the site of their transcription start and termination sites. The top transcript 637 is predicted to have high coding potential through CPAT. The bottom graphs individually delineate 638 the difference in mean counts between cases and controls in the expression of the gene and its 639 constituent isoforms. The rightmost graph indicates the isoform expression as a proportion of the total 640 expression across all isoforms within cases and controls separately, indicating a greater proportion of 641 expression for the coding variant and a decreased proportion of expression for the second non-coding 642 variant.

643

### 644 **Tables**

- **Table 1.** Overlap of transcriptome-wide significant differences between MND cases and controls
- from STAR and Salmon models with log2 fold change and Benjamini-Hochberg adjusted *p*-values.
- 647 Bolded names are significant in both models. lncRNA: long non-coding RNA; PC: protein coding;
- 648 PP: processed pseudogene; UP: Unprocessed pseudogene; TUP: transcribed unprocessed pseudogene.

Name         Clas         Stat         Length         Type         Description         length C         length C<							STAR		Salmon			
$ \begin{array}{c} AC0044011 & 19 & 221029 & 3037 heIRNA & Neel ranker p, statemas to dell \\ - & - & - & - & - & 0.00 & 0.27 & 57 + 10^{-5} \\ AC0108781 & 2 & 37816915 & 1047 & PB \\ Sectical/teconic kines cospto \\ secondages \\ AC012275.1 & 2 & 119 476 428 & 1049 & heIRNA & Sett anticens to atcl \\ AC0268584 & 11 & 1734621 & 2033 & PC \\ AC0268584 & 11 & 1734621 & 2033 & PC \\ AC0268584 & 11 & 1734621 & 2038 & PC \\ AC0268584 & 11 & 1734621 & 2038 & PC \\ AC0268584 & 11 & 1734621 & 2038 & PC \\ AC0268584 & 11 & 1734621 & 2038 & PC \\ AC0268584 & 11 & 1734621 & 2038 & PC \\ AC0268584 & 11 & 1734621 & 2038 & PC \\ AC0268584 & 11 & 1734621 & 2038 & PC \\ AC0268 & 19 & 11374602 & 2048 & PC \\ AC012761 & 15 & 412702 & 1544 & PC \\ AC11 & 218 & 10470 & 106422 & PC \\ A74b dyperation compact for antices to atcl \\ AC012 & 11 & 104728 & 1049 & PC \\ A41516452 & 11 & 1992796 & 9181 & PC \\ AAlyter report domain 1 & 224 & 0.47 & 14.8 & 10^{-2} & -1.54 & 0.47 & 20.8 & 12.8 & 10^{-4} \\ AKNRD1 & 11 & 92208453 & 1140 & PC \\ AAlyter report domain 1 & 244 & 0.47 & 14.8 & 10^{-4} & -0.88 & 0.22 & 0.10^{-4} & -0.88 & 0.22 & 0.10^{-5} & -0.88 & 0.12 & 2.18 & 10^{-3} \\ ANN1 & 14 & 5728924 & 2918 & PC \\ AAlyter report domain 1 & 224 & 0.47 & 14.8 & 10^{-3} & -0.48 & 0.44 & 10.4 & 13.8 & 10^{-3} \\ ANN1 & 14 & 5728924 & 2918 & PC & Alayter report domain 1 & 224 & 0.47 & 14.8 & 10^{-3} & -0.48 & 0.44 & 10.4 & 13.8 & 10^{-3} \\ ANN1 & 14 & 5728924 & 2918 & PC & Alayter report domain 1 & 224 & 0.47 & 14.8 & 10^{-3} & -0.48 & 0.44 & 14.8 & 10^{-3} \\ ANN1 & 14 & 5728924 & 2918 & PC & Alayter report nototice agala & 0.47 & 0.48 & 0.47 & 14.8 & 10^{-3} & -0.48 & 0.44 & 14.8 & 10^{-3} \\ ANN1 & 14 & 5728924 & 2918 & PC & Alayter report nototice agala & 0.47 & 0.48 & 0.41 & 13.8 & 10^{-7} \\ CIRKNA & 2 & 1714752 & 205816 & PC & Cyclin dependent kinese inhibitor gin. & 0.47 & 0.48 & 0.44 & 14.8 & 10^{-3} \\ CIRKNA & 2 & 1714752 & 205816 & PC & Cyclin dependent kinese inhibitor gin. & 0.48 & 0.14 & 14.8 & 10^{-7} \\ CIRKNA & 2 & 1714752 & 20586 & 20577 & 1048 & 1048 & 1048 & 10$	Name	$\operatorname{Chr}$	Start	Length	Type	Description	$\log_2 FC$	$\log_2 SE$	p	$\log_2 FC$	$\log_2 SE$	p
$ \begin{array}{c} AC010578.1 & 2 & 37.816915 & 1047 & PP & Serin of Incomine Issue receptor \\ AC01275.1 & 2 & 119.476.428 & 10919 & hasRNS & Steratistess re n.1 & -2.96 & 0.71 & 6.9 \times 10^{-4} & 2.80 & 0.63 & 5.4 \times 10^{-4} \\ AC005711 & 1 & 37.756.4 & 9.87 & Max & Novel proteins of the series 1 & 0.31 & 0.33 & 10^{-1} & 0.02 & 0.12 & 0.13 & 2.7 \times 10^{-2} \\ AC05711 & 1 & 37.756.4 & 9.87 & Max & Novel proteins of the series 1 & 0.23 & 0.33 & 10^{-1} & 0.03 & 0.21 & 0.25 & 0.12 & 0.11 & 2.8 \times 10^{-5} \\ AC05711 & 1 & 37.756.4 & 9.87 & Max & Novel proteins of the series 1 & 0.25 & 0.11 & 0.24 & 0.12 & 0.11 & 2.8 \times 10^{-5} \\ AC0570 & 19 & 11.576.60 & 4380 & PC & Actin alpha certifice model 1 & 1.25 & 0.11 & 2.1 \times 10^{-2} & 2.09 & 0.49 & 2.8 \times 10^{-5} \\ AC10370 & 1.16 & 2.2716.71 & 0.6622 & PF & Novel proteins of the series 1 & 1.25 & 0.11 & 2.1 \times 10^{-2} & 2.09 & 0.49 & 2.8 \times 10^{-5} \\ AC10370 & 1.16 & 0.991206 & 918. & PC & Actin alpha certifice model 1 & 2.45 & 0.63 & 1.1 \times 10^{-2} & 2.09 & 0.49 & 2.8 \times 10^{-5} \\ AL307052 & 13 & 10122208 & 2.971 & TE & Te & -1.88 & 0.54 & 1.1 \times 10^{-4} & 2.61 & 0.48 & 8.8 \times 10^{-5} \\ AL307052 & 13 & 10122208 & 2.971 & TE & Te & -1.88 & 0.54 & 1.1 \times 10^{-2} & 0.14 & 0.47 & 2.0 \times 10^{-4} \\ AL307052 & 13 & 1012208 & 1027 & TE & Te & -1.88 & 0.54 & 1.1 \times 10^{-2} & 0.18 & 0.14 & 1.4 \times 10^{-3} \\ AL307052 & 12 & 5730690 & 53110 & PC & Ap27 metalop protein complex 5 & 0.17 & 0.04 & 7.3 \times 10^{-6} & 0.18 & 0.14 & 1.8 \times 10^{-1} \\ AL307052 & 12 & 5730539 & 36513 & PC & Cyclin dependent Himse full hout 0 & 0.24 & 0.02 & 0.5 \times 10^{-2} & 1.02 & 0.18 & 1.0 \times 10^{-2} \\ CDK14 & 12 & 574777 & 7857 & PC & Cyclin dependent Himses Hallow 2 & 0.48 & 3.1 \times 10^{-4} & 1.04 & 0.43 & 1.0 \times 10^{-2} \\ CDK21 & 1 & 2017991 & 7774 & PC & Childings of the moxel 1 & 0.80 & 0.3 & 0.10^{-2} & 1.24 & 0.05 & 0.3 \times 10^{-1} \\ CDK14 & 12 & 0.57567 & 345918 & PC & Colonegate receptor isolutial alph - 0.44 & 0.43 & 1.0^{-5} & 1.24 & 0.45 & 1.4 \times 10^{-5} \\ CDK21 & 1 & 20174910 & 7774 & PS & TF & Childings of the moxel 1 & 1.09 & 0.24 & 1$	AC004490.1	19	2212029	3537	lncBNA	Novel transcript, antisense to dot11	_	_	_	0.80	0.20	$5.7 \times 10^{-5}$
$ \begin{array}{c} \text{associated protein (strep)} \\ associated protein ($	AC010878.1	2	37816915	1047	PP	Serine/threenine kinase receptor	2.17	0.56	$1.0 \times 10^{-4}$	2.89	0.63	$5.4 \times 10^{-6}$
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $						associated protein (strap)						
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$						pseudogene						
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	AC013275.1	2	119476428	10919	lncRNA	Sctr antisense rna 1	-2.96	0.74	$6.0  imes 10^{-5}$	-2.98	0.72	$4.0  imes 10^{-5}$
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	AC068580.4	11	1734821	29134	PC	Novel protein	0.57	0.30	$5.9  imes 10^{-2}$	1.79	0.41	$1.3  imes 10^{-5}$
$ \begin{array}{c} AC103740.1 & 15 & 02.27675 & 56360 & hcRNA & Novel ranserpt, anticense to the 2 & 0.79 & 0.13 & 3.8 \times 10^{-5} & 0.03 & 0.12 & 8.1 \times 10^{-7} \\ ACPG & 10 & 115.7466 & 4340 & PC & Acid plaphates 4, tartark = 0.40 & 0.28 & 7.4 \times 10^{-5} & 1.46 & 0.53 & 8.8 \times 10^{-5} \\ ATRIC & 5 & 12.25771 & 166637 & PC & Acid plaphates 4, tartark = 0.40 & 0.28 & 7.4 \times 10^{-5} & 1.46 & 0.53 & 8.8 \times 10^{-5} \\ ATRIC & 5 & 12.25771 & 166637 & PC & Acid plaphates 6, tartark = 0.42 & 0.42 & 0.47 & 2.48 & 10^{-5} & 2.60 & 0.48 & 8.4 \times 10^{-5} \\ ANKRD1 & 10 & 0902096 & 9181 & PC & Ankytrin roped domain 1 & 2.24 & 0.47 & 1.48 \times 10^{-6} & 2.61 & 0.47 & 2.0 \times 10^{-5} \\ ANKRD1 & 10 & 0902096 & 9181 & PC & Ankytrin roped domain 1 & 2.24 & 0.47 & 1.48 \times 10^{-5} & 0.48 & 0.14 & 1.5 \times 10^{-5} \\ AP53M1 & 14 & 57268924 & 29819 & PC & Ankytrin roped domain 1 & 2.24 & 0.47 & 1.48 \times 10^{-5} & 0.48 & 0.14 & 1.5 \times 10^{-5} \\ BMSIP1 & 10 & 73715843 & 14027 & TUP & Dinsi periodepring these ad at p & -0.30 & 0.17 & 6.9 \times 10^{-2} & -1.22 & 0.28 & 1.8 \times 10^{-5} \\ DINSIP1 & 10 & 73715843 & 14027 & TUP & Dinsi periodepring these ad at p & 0.24 & 0.10 & 1.4 \times 10^{-3} & 0.44 & 0.14 & 1.3 \times 10^{-3} \\ CIRNA1 & 2 & 1271777 & 8287 & PC & Cyclin dependent kines 4 & 0.12 & 0.06 & 0.18 & 0.14 & 1.4 \times 10^{-3} \\ CIRNA1 & 2 & 1271777 & 8287 & PC & Cyclin dependent kines 4 & 0.12 & 0.06 & 0.18 \times 10^{-5} & 1.48 & 0.04 & 0.13 & 6.7 \times 10^{-7} \\ CIN1 & 1 & 3 & 578652 & 345013 & PC & Collagen type xix alpha 1 chain & 2.26 & 0.48 & 3.18 & 0.50 & 3.1 \times 10^{-6} \\ DCL2A1 & 1 & 10880872 & 32455 & hcRM & Deleci fi in primocritic lapha & 0.99 & 0.24 & 2.8 \times 10^{-5} & 1.43 & 0.37 & 1.4 \times 10^{-5} \\ DCL2M1 & 13 & 3578652 & 326255 & PC & Doubcertin Hile kines 1 & 1.08 & 0.19 & 0.48 & 4.1 \times 10^{-5} & 1.43 & 0.03 & 1.3 \times 10^{-6} \\ DCL2M1 & 13 & 3578652 & 326255 & PC & Doubcertin hynding domain 7 & 0.77 & 0.16 & 8.7 \times 10^{-7} & 0.34 & 0.33 & 3.0 \times 10^{-7} \\ DCL2M1 & 13 & 3578652 & 326255 & PC & Doubcertin hynding domain 7 & 0.77 & 0.16 & 8.7 \times 10^{-7} & 0.34 & 0.33 & 1.3 \times 10^{-6} \\ DC$	AC087457.1	15	34755084	58422	$\ln c R N A$	Novel transcript, antisense to actc1	1.61	0.36	$6.0 imes10^{-6}$	0.42	0.15	$5.7 imes10^{-3}$
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	AC103740.1	15	62827675	56360	lncRNA	Novel transcript, antisense to tln2	0.79	0.13	$3.3  imes 10^{-9}$	0.03	0.12	$8.1  imes 10^{-1}$
$ \begin{array}{c} \mbox{resistant} \\ ACTC1 & 5 & 27 & 70 \\ ARRN & 5 & 27 & 70 \\ ARRN & 5 & 27 & 70 \\ ARRN & 16602 & 12 \\ A110665 & 14 \\ A122018 & 220 & 28 \\ A11065 & 21 & 10 \\ A12305 & 200 \\ A11065 & 21 & 10 \\ A12305 & 200 \\ A12305 & 200 \\ A110 & 102308 & 200 \\ A110 & 110 & 101 & 100 \\ A110 & 110 & 101 & 100 \\ A110 & 110 & 101 & 100 \\ A110 & 100 & 101 & 100 \\ A110 & 100 & 101 & 100 \\ A110 & 100 & 100 & 100 & 100 \\ A110 & 100 & 100 & 100 & 100 \\ A110 & 100 & 100 & 100 & 100 \\ A110 & 100 & 100 & 100 & 100 \\ A110 & 100 & 100 & 100 & 100 & 100 \\ A110 & 100 & 100 & 100 & 100 & 100 \\ A110 & 100 & 100 & 100 & 100 & 100 & 100 \\ A110 & 100 & 100 & 100 & 100 & 100 & 100 & 100 & 100 & 100 & 100 \\ A110 & 1000 & 100 & 1000 & 1000 & 1000 & 1000 & 1000 & 1000 & 1000 & 1000 &$	ACP5	19	11574660	4349	$\mathbf{PC}$	Acid phosphatase 5, tartrate	-0.49	0.28	$7.4 \times 10^{-2}$	-1.54	0.37	$3.8 \times 10^{-5}$
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$						resistant						-
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	ACTC1	15	34790230	5320	PC	Actin alpha cardiac muscle 1	1.25	0.41	$2.1 \times 10^{-3}$	2.09	0.49	$2.3 \times 10^{-5}$
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	AHRR	5	271670	166622	PC	Aryl-hydrocarbon receptor repressor	4.25	0.89	$2.0 \times 10^{-6}$	2.84	0.64	$8.8 \times 10^{-6}$
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	AL161665.2	14	32200433	1304	IncRNA	Novel transcript	-0.98	0.22	$8.0 \times 10^{-6}$	-0.89	0.23	$1.2 \times 10^{-4}$
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	AL390755.2	13	110123208	2027	TEC	Tec	1.38	0.54	$1.1 \times 10^{-2}$	3.57	0.87	$4.4 \times 10^{-5}$
ArbSil 14 57268924 29519 PC Adaptor related protein complex 5 0.17 0.04 73 $\times 10^{-5}$ 0.18 0.14 1.9 $\times 10^{-5}$ atlumit mu 1 atlumit mu 1 ATP23 12 57906039 53110 PC Atp23 metallopeptidase and atp $-0.30$ 0.17 6.9 $\times 10^{-2}$ $-1.22$ 0.28 1.8 $\times 10^{-5}$ Synthase assembly fintor homolog DISIP 10 73715843 14627 TUP Bins1 pseudogene 4 0.42 0.10 29 $\times 10^{-5}$ 0.44 0.14 1.3 $\times 10^{-3}$ CDK4 12 5774777 8287 PC Cyclin dependent kinase inlibitor 2b 0.44 0.12 0.06 35 $\times 10^{-2}$ 0.16 0.31 6.7 $\times 10^{-5}$ CDK4 12 5774777 8287 PC Cyclin dependent kinase inlibitor 2b 0.44 0.14 1.4 $\times 10^{-5}$ 0.78 0.24 1.4 $\times 10^{-3}$ CDK4 12 1071747592 40344 PC Cohinesgic receptor nicotinic alpha 0.99 0.22 0.8 $\times 10^{-5}$ 1.02 0.03 1.4 $\times 10^{-3}$ COL19A1 6 0986555 345013 PC Collegan ppe xix alpha 1 chain 1.22 0.04 30 0.14 31.0^{-4} 1.16 0.37 1.15 $\times 10^{-5}$ COL29A1 4 10888723 494028 PC Collegan type xix alpha 1 chain 1.22 0.04 8 3.1 $\times 10^{-4}$ 1.06 0.37 1.15 $\times 10^{-5}$ DECUL 1 6547082 3555 IncRNA Detect in lymphocytic leukemia 2 1.09 0.18 4.1 $\times 10^{-9}$ 1.34 0.24 1.3 $\times 10^{-6}$ EFC 16 571667 1.16 5523372 49222 PC E Echand calcium linding domain 7 0.77 0.18 8.7 $\times 10^{-7}$ 0.34 0.33 0.8 $\times 10^{-7}$ EFS 5 5440626 6659 PC Follistatin 1.39 0.50 1.55 $\times 10^{-4}$ 1.14 0.27 2.3 $\times 10^{-5}$ EKR15 0 12 52108906 23019 PC Kertaria 80 1.105 0.53 2.5 $\times 10^{-4}$ 1.04 0.27 2.3 $\times 10^{-5}$ ERCM 15 7.1627 $\times 10^{-6}$ IncRNA Long intergenic non-protein coding $  -$ 0.26 0.4 $\times 10^{-1}$ IncRNA Long intergenic non-protein coding $  -$ 0.26 0.17 $\times 10^{-5}$ 0.022 0.26 6.4 $\times 10^{-1}$ IncRNA Long intergenic non-protein coding $  -$ 0.40 0.29 5.8 $\times 10^{-5}$ ILCMT1-AS1 16 8578 HC 20 IncRNA Long intergenic non-protein coding $  -$ 0.40 0.27 5.8 $\times 10^{-5}$ ILCMT1-AS1 16 8578 HC 20 MC 10 1055 PC Metry for the order and $-0.50$ 0.01 1.1 $\times 10^{-5}$ 0.022 0.26 6.4 $\times 10^{-1}$ Irras 211 ILN00062 1 108774 hCRNA Long intergenic non-protein coding $  -$ 1.18 0.28 2.9 $\times 10^{-5}$ MCC1 1 3986426 631 735 PP Mc-c3 genedogene 39 $ -$	ANKRD1	10	90 912 096	9181	PC	Ankyrin repeat domain 1	2.24	0.47	$1.4 \times 10^{-6}$	2.61	0.47	$2.0 \times 10^{-8}$
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	AP5M1	14	57268924	29819	PC	Adaptor related protein complex 5	0.17	0.04	$7.3 \times 10^{-6}$	0.18	0.14	$1.9 \times 10^{-1}$
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$		10	55,000,000	50.110	DC	subunit mu l	0.00	0.17	0.010-2	1.00	0.00	1.010=5
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	ATP23	12	57 906 039	53 110	PU	Atp23 metallopeptidase and atp	-0.30	0.17	$0.9 \times 10^{-2}$	-1.22	0.28	$1.8 \times 10^{-5}$
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	DMC1D4	10	79715049	14.007	TUD	Synthase assembly factor homolog	0.49	0.10	0.010-5	0.44	0.14	1.210-3
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	DM51P4 CDV4	10	13113843	14027	DC	Binsi pseudogene 4	0.42	0.10	$2.9 \times 10^{-2}$	0.44	0.14	$1.3 \times 10^{-2}$
$ \begin{array}{c} \text{CHALSD} & 5 & 22002.935 \\ \text{CHALSD} & 5 & 22002.935 \\ \text{CHIRAL} & 20137802 \\ \text{CHIRAL} & 20137432 \\ \text{CHIRAL} & 201374747392 \\ \text{CHIRAL} & 12 & 1717475392 \\ \text{Chilmseg3 ince receptor nicotinic alpha \\ \text{COL19A1} & 6 \\ 0.9860556 \\ \text{345913} & \text{PC} \\ \text{Clolingent treesceptor nicotinic alpha \\ \text{Lokin} & 2.26 \\ \text{Clolingent treesceptor nicotinic alpha \\ \text{Lokin} & 2.26 \\ \text{Clolingent treesceptor nicotinic alpha \\ \text{Lokin} & 2.26 \\ \text{Clolingent treesceptor nicotinic alpha \\ \text{Lokin} & 2.26 \\ \text{Clolingent treesceptor nicotinic alpha \\ \text{Lokin} & 2.26 \\ \text{Clolingent treesceptor nicotinic alpha \\ \text{Lokin} & 2.5 \\ \text{LCLL} & 13 \\ \text{S5768}652 \\ \text{35768}652 \\ \text{35263572 \\ \text{49222} \\ \text{S576 \\ \text{FFC} & 1 \\ \text{6} 63523372 \\ \text{49222 \\ \text{49222} \\ \text{FFC} \\ \text{EFCAB7 \\ \text{1} & 63526366 \\ \text{5577 \\ \text{5} \\ \text{5480062 \\ \text{6660} \\ \text{6660} \\ \text{CFS1} \\ \text{5} \\ $	CDK4 CDKN9D	12	01141121	8281	PU	Cuclin dependent kinase 4	0.12	0.00	$3.0 \times 10^{-5}$	0.04	0.13	$0.7 \times 10^{-3}$
$ \begin{array}{c} \text{CHISAI} & 1 & 213 17831 & 174 & 176 & \text{Clutimase 3 like 1} & 2.39 & 0.39 & 0.34 & 30 & 10 & 1.00 & 0.34 & 2.5 & 10^{-5} \\ \text{CRINAI } & 1 & 211741752 & 40344 & PC & \text{Clutimase 3 like 1} & 2.38 & 10^{-5} & 1.22 & 0.28 & 10^{-5} & 1.22 & 0.28 & 10^{-5} & 1.22 & 0.28 & 10^{-5} & 1.22 & 0.28 & 10^{-5} & 1.22 & 0.28 & 10^{-5} & 1.22 & 0.28 & 10^{-5} & 1.22 & 0.28 & 10^{-5} & 1.22 & 0.28 & 10^{-5} & 1.22 & 0.28 & 10^{-5} & 1.25 & 0.28 & 10^{-5} & 1.25 & 0.28 & 10^{-5} & 1.25 & 0.28 & 10^{-5} & 1.28 & 0.28 & 10^{-5} & 1.28 & 0.28 & 10^{-5} & 1.28 & 0.28 & 10^{-5} & 1.28 & 0.28 & 10^{-5} & 1.28 & 0.28 & 10^{-5} & 1.28 & 0.28 & 10^{-5} & 1.28 & 0.28 & 10^{-5} & 1.28 & 0.28 & 10^{-5} & 1.28 & 0.28 & 10^{-5} & 1.28 & 0.28 & 10^{-5} & 1.28 & 0.28 & 10^{-5} & 1.28 & 0.28 & 10^{-5} & 1.28 & 0.28 & 1.28 & 10^{-5} & 1.28 & 0.28 & 1.28 & 10^{-5} & 1.28 & 0.28 & 10$	CHI2L1	9	22 002 903	0405	PC	Cyclin dependent kinase minipitor 20 Chitinaga 2 lika 1	0.64	0.19	$1.4 \times 10^{-1}$ 2.0 $\times 10^{-6}$	1.04	0.24	$1.4 \times 10^{-3}$
$ \begin{array}{c} \text{CRUMAR} & 2 & \text{IFAPT 352} & \text{IOAPT} & \text{IFC} & \text{Collingent treeport module applies} & 0.23 & 0.24 & 2.8 \times 10^{-1} & 1.22 & 0.23 & 1.0 \times 10^{-1} \\ \text{COL19A1} & 6 & 6986556 & 345913 & \text{PC} & \text{Collagen type exis alpha 1 chain} & 2.26 & 0.48 & 3.1 \times 10^{-6} & 1.16 & 0.37 & 1.9 \times 10^{-3} & 1.0 \\ \text{COL2A1} & 10 & 8086725 & 494028 & 2355 & \text{IncRN} & Deleted in hymphocytic leukenia 2 & 1.09 & 0.18 & 4.1 \times 10^{-9} & 1.45 & 0.30 & 1.3 \times 10^{-6} \\ \text{DEUEV1} & 6 & 35768652 & 326255 & \text{PC} & \text{Collagen type exis alpha 1 chain} & 1.72 & 0.41 & 4.1 \times 10^{-9} & 1.45 & 0.30 & 1.3 \times 10^{-6} \\ \text{DEUEV1} & 6 & 576862 & 326255 & \text{IncRN} & Deleted in hymphocytic leukenia 2 & 1.09 & 0.18 & 4.1 \times 10^{-9} & 1.34 & 0.24 & 1.3 \times 10^{-6} \\ \text{DEUEV1} & 5 & 74627406 & 14019 & \text{PC} & \text{Ectodermal-neural cortex 1} & 0.77 & 0.16 & 8.7 \times 10^{-7} & 0.34 & 0.33 & 3.0 \times 10^{-1} \\ \text{ENC1} & 5 & 74627406 & 14019 & \text{PC} & \text{Ectodermal-neural cortex 1} & 0.36 & 0.14 & 7.8 \times 10^{-3} & 1.27 & 0.28 & 4.9 \times 10^{-6} \\ \text{IKRS0} & 12 & 52168906 & 23019 & \text{PC} & Keratin ato: neuroner transmitted in the state in the sta$	CHENAI	1	203178931	40.944	PC	Chalinargia recentor nicotinia alpha	2.50	0.49	$3.0 \times 10$ $2.8 \times 10^{-5}$	1.04	0.34	$2.3 \times 10$ $1.6 \times 10^{-5}$
$ \begin{array}{c} \text{COL19A1} & 6 & 69866556 & 345913 & \text{PC}} & \text{Collagen type xix alpha 1 chain} & 2.26 & 0.48 & 3.1 \times 10^{-6} & 1.16 & 0.37 & 1.9 \times 10^{-3} \\ \text{COL2SA1} & 4 & 108808725 & 494028 & \text{PC} & \text{Collagen type xix alpha 1 chain} & 1.07 & 0.14 & 2.5 \times 10^{-6} & 1.46 & 0.50 & 1.3 \times 10^{-6} \\ \text{DLEVL1} & 1 & 63523372 & 494028 & \text{PC} & \text{Collagen type xix alpha 1 chain} & 1.08 & 0.19 & 2.6 \times 10^{-8} & 1.48 & 0.50 & 3.1 \times 10^{-6} \\ \text{DLEV21} & 1 & 63523372 & 49322 & \text{PC} & \text{El-hand calcium binding domain 7} & 0.77 & 0.16 & 8.7 \times 10^{-7} & 0.34 & 0.33 & 0.0 \times 10^{-1} \\ \text{EFCAB7} & 5 & 53480626 & 6509 & \text{PC} & \text{Follistatin} & 1.39 & 0.31 & 7.5 \times 10^{-6} & 1.87 & 0.39 & 1.2 \times 10^{-6} \\ \text{FST} & 5 & 53480626 & 6509 & \text{PC} & \text{Follistatin} & 0.39 & 0.31 & 7.5 \times 10^{-6} & 1.87 & 0.39 & 1.2 \times 10^{-6} \\ \text{LNC00211} & 2 & 57880642 & 3069 & 23019 & \text{C} & \text{Keratin 80} & 1.93 & 0.31 & 7.5 \times 10^{-6} & 1.27 & 0.28 & 4.9 \times 10^{-6} \\ \text{LNC00211} & 2 & 37820498 & 55777 & \lncRNA & Long intergenic non-protein coding & -1 & -1 & -362 & 0.71 & 3.8 \times 10^{-7} \\ \text{CMT1-AS1} & 16 & 25085168 & 23.349 & \text{PC} & \text{Loutine rich repeats and & 0.50 & 0.31 & 1.1 \times 10^{-3} & 0.22 & 0.26 & 9.4 \times 10^{-1} \\ \text{INC00262} & 1 & 108784012 & 8875 & \ln cRNA & Long intergenic non-protein coding & -1 & -1 & -362 & 0.71 & 3.8 \times 10^{-7} \\ \text{MRCN3} & 7 & 111091006 & 3449 & \text{PC} & \text{Loutine rich repeats and & 0.50 & 0.31 & 1.1 \times 10^{-2} & 1.43 & 0.34 & 2.1 \times 10^{-5} \\ \text{MTCO3P39} & 4 & 49246021 & 518 & \text{PP} & \text{Mt-co3} pseudogene 39 & & - & - & -0.94 & 0.21 & 7.1 \times 10^{-6} \\ \text{MTCO3P39} & 4 & 49246021 & 518 & \text{PP} & \text{Mt-co3} pseudogene 32 & & - & - & - & -1.18 & 0.32 & 2.9 \times 10^{-5} \\ \text{MTCO3P39} & 4 & 49246021 & 518 & \text{PP} & \text{Mt-co3} pseudogene 39 & & - & - & - & - & -1.88 & 0.28 & 2.9 \times 10^{-5} \\ \text{MTCO3P39} & 4 & 49246021 & 518 & \text{PP} & \text{Mt-co3} pseudogene 39 & & - & - & - & - & - & 0.44 & 0.41 \times 1.5 \times 10^{-6} & 0.23 & 0.33 & 5.5 \times 10^{-2} & 1.43 & 0.34 & 2.1 \times 10^{-5} \\ \text{MTCO3P39} & 4 & 49246$	onnivai	4	114141002	40.044	10	1 submit	0.55	0.24	2.0 × 10	1.44	0.20	$1.0 \times 10$
$ \begin{array}{c} \text{COLSAIT} & 0 & $	COL19A1	6	69 866 556	345.013	PC	Collagen type vix alpha 1 chain	2.26	0.48	$3.1 \times 10^{-6}$	1.16	0.37	$1.9 \times 10^{-3}$
$ \begin{array}{c} \text{CDCDAT} & 13 & 35786652 & 362255 & \text{PC} & \text{Doublecorrin} & \text{Ike} & \text{kinase} 1 & 1.08 & 0.19 & 2.6 \times 10^{-8} & 1.45 & 0.30 & 0.13 \times 10^{-6} \\ \text{DLEU2L} & 1 & 63 5736652 & 362255 & \text{PC} & \text{Doublecorrin} & \text{Ike} & \text{kinase} 1 & 1.08 & 0.19 & 2.6 \times 10^{-8} & 1.45 & 0.30 & 0.13 \times 10^{-6} \\ \text{DLEU2L} & 1 & 63 57372 & 49322 & \text{PC} & \text{E-hand} calcium binding domain 7 & 0.77 & 0.16 & 8.7 \times 10^{-7} & 0.34 & 0.33 & 3.0 \times 10^{-1} \\ \text{EFCAB7} & 1 & 63 523372 & 49322 & \text{PC} & \text{E-hand} calcium binding domain 7 & 0.77 & 0.16 & 8.7 \times 10^{-7} & 0.34 & 0.33 & 3.0 \times 10^{-1} \\ \text{EFC} & 7 & 127 & 0.24 & 61 4019 & \text{PC} & \text{Ectodermal-envaluation} & 1.09 & 0.31 & 7.5 \times 10^{-6} & 1.48 & 0.37 & 1.27 \\ \text{FST} & 5 & 53 480 626 & 6509 & \text{PC} & \text{Follistatin} & 0 & 1.05 & 0.53 & 2.2 \times 10^{-4} & 2.76 & 0.54 & 3.7 \times 10^{-7} \\ \text{LCMT1-AS1} & 16 & 25 085168 & 26388 & \text{IncRNA} & \text{Long intergenic non-protein coding} & 2.14 & 0.50 & 1.7 \times 10^{-5} & 0.02 & 0.26 & 9.4 \times 10^{-1} \\ \text{INC00626} & 1 & 168 784012 & 8875 & \text{IncRNA} & \text{Long intergenic non-protein coding} & - & - & - & 3.62 & 0.71 & 3.8 \times 10^{-7} \\ \text{rma} 211 & \text{LINC00626} & 1 & 168 784012 & 8875 & \text{IncRNA} & \text{Long intergenic non-protein coding} & - & - & - & - & 3.62 & 0.71 & 3.8 \times 10^{-5} \\ \text{LIRRN3} & 7 & 111 091006 & 34449 & \text{PC} & \text{Leucine rich repeat neuronal 3} & 0.27 & 0.16 & 8.5 \times 10^{-2} & 1.43 & 0.34 & 2.1 \times 10^{-5} \\ \text{MTCO3P39} & 4 & 4924601 & 318 & \text{PP} & \text{Mt-co3 pseudogene} 3p & - & - & - & 0.94 & 0.21 & 7.5 \times 10^{-6} \\ \text{MTCO3P39} & 4 & 4924601 & 518 & \text{PP} & \text{Mt-co3 pseudogene} 2p & - & - & - & 0.44 & 0.24 & 7.1 \times 10^{-6} \\ \text{MTCO3P39} & 4 & 4924601 & 518 & \text{PP} & \text{Mt-co3 pseudogene} 2p & - & - & - & 0.44 & 0.24 & 7.4 \times 10^{-5} \\ \text{MUC19} & 12 & 4938365 & 177.488 & \text{PC} & \text{Mucin 19, 0.100meric} & -0.03 & 0.14 & 4.1 \times 10^{-6} & 3.22 & 0.77 & 2.7 \times 10^{-5} \\ \text{MUC19} & 12 & 49234661 & 8171 & \text{PC} & \text{Nucin 19, 0.100meric} & -0.05 & 0.07 & 4.8 \times 10^{-1} & -0.27 & 0.07 & 4.4 \times 10^{-5} \\ \text{PEG10} & 7 & 94656325 & 13371 & \text{PC} & Nucin 1$	COL25A1	4	108 808 725	404.028	PC	Collagen type xix alpha 1 chain	1 79	0.40	$-2.5 \times 10^{-5}$	3.18	0.51	$3.1 \times 10^{-10}$
$ \begin{array}{c} \textbf{DEEVL} & 1 & 6357092 \\ \textbf{DEEVL} & 1 & 63523372 \\ \textbf{4}9322 & \textbf{PC} & \textbf{E1-hand calcium binding domain 7 \\ \textbf{ike} & 0.77 \\ \textbf{0}.16 & 8.7 \times 10^{-7} & 0.34 \\ \textbf{0}.24 & 1.4 & 0.27 \\ \textbf{2}.3 \times 10^{-5} \\ \textbf{1}.4 & 0.28 \\ \textbf{2}.4 & 0.50 \\ \textbf{1}.7 \times 10^{-5} \\ \textbf{0}.2 \\ \textbf{2}.4 & 0.50 \\ \textbf{1}.7 \times 10^{-5} \\ \textbf{0}.2 \\ \textbf{2}.4 \\ \textbf{2}.4 \\ \textbf{1}.4 \\ \textbf{1}.1 \\ \textbf{2} \\ \textbf{2}.4 \\ \textbf{1}.4 \\ \textbf{1}.1 \\ \textbf{2} \\ \textbf{2} \\ \textbf{1}.4 \\ \textbf{1}.1 \\ \textbf{1} \\ \textbf{2} \\ \textbf{1} \\ \textbf{1} \\ \textbf{1} \\ \textbf{1} \\ \textbf{1} \\ \textbf{1} \\ \textbf{2} \\ \textbf{1} $	DCLK1	13	35 768 652	362 655	PC	Doublecortin like kinase 1	1.08	0.19	$2.6 \times 10^{-8}$	1.45	0.30	$1.3 \times 10^{-6}$
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	DLEU2L	1	63 547 082	3555	IncBNA	Deleted in lymphocytic leukemia 2	1.00	0.15	$4.1 \times 10^{-9}$	1.40	0.24	$1.3 \times 10^{-8}$
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	DDD0 <b>-</b> D		00011002	0000	monthin	like	1100	0110	111 // 10	1101	0.21	110 / 10
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	EFCAB7	1	63523372	49322	$\mathbf{PC}$	Ef-hand calcium binding domain 7	0.77	0.16	$8.7 \times 10^{-7}$	0.34	0.33	$3.0 \times 10^{-1}$
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	ENC1	5	74627406	14019	PC	Ectodermal-neural cortex 1	0.70	0.21	$7.5 \times 10^{-4}$	1.14	0.27	$2.3 \times 10^{-5}$
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	FST	5	53480626	6509	$\overline{PC}$	Follistatin	1.39	0.31	$7.5 \times 10^{-6}$	1.87	0.39	$1.2 \times 10^{-6}$
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	KRT80	12	52168996	23019	$\overline{PC}$	Keratin 80	1.95	0.53	$2.2 \times 10^{-4}$	2.76	0.54	$3.7 \times 10^{-7}$
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	LCMT1-AS1	16	25085168	26388	lncRNA	Lcmt1 antisense rna 1	0.36	0.14	$7.8 \times 10^{-3}$	1.27	0.28	$4.9 \times 10^{-6}$
$ \begin{array}{c} \mbox{rma 211} \\ \mbox{rma 211} \\ \mbox{LinkC00626} & 1 & 168784012 & 8875 & \ln c RNA \\ \mbox{Long intergenic non-protein coding} & - & - & - & - & - & - & 3.62 & 0.71 & 3.8 \times 10^{-7} \\ \mbox{rma 626} \\ \mbox{LRRN3} & 7 & 111001006 & 34449 & PC \\ \mbox{Lexcine rich repeats and} & 0.27 & 0.16 & 8.5 \times 10^{-2} & 1.43 & 0.34 & 2.1 \times 10^{-5} \\ \mbox{LRRM1} & 3 & 54918231 & 48858 & PC \\ \mbox{Lexcine rich repeats and} & 0.50 & 0.31 & 1.1 \times 10^{-1} & 2.95 & 0.68 & 1.2 \times 10^{-5} \\ \mbox{transmuchand columins 1} \\ \mbox{MERTK} & 2 & 111808607 & 130955 & PC \\ \mbox{Mer Proto-oncogene, tyrosine kinase} & -0.63 & 0.14 & 4.1 \times 10^{-6} & -0.80 & 0.29 & 5.8 \times 10^{-3} \\ \mbox{MTCO3P39} & 4 & 49246601 & 315 & PP \\ \mbox{Mt-co3 pseudogene 39} & - & - & - & 0.94 & 0.21 & 7.1 \times 10^{-6} \\ \mbox{MTND3P22} & 4 & 49246601 & 315 & PP \\ \mbox{Mt-co3 pseudogene 22} & - & - & - & - & 1.18 & 0.28 & 2.9 \times 10^{-5} \\ \mbox{MUC19} & 12 & 40393.395 & 177.438 & PC \\ \mbox{Muc1 19, 016} \text{obsource} & -0.37 & 0.39 & 3.5 \times 10^{-1} & 3.22 & 0.77 & 2.7 \times 10^{-5} \\ \mbox{MVCL} & 1 & 39895426 & 6831 & PC \\ \mbox{Mycl proto-oncogene, bhh} & 1.40 & 0.36 & 1.1 \times 10^{-4} & 1.90 & 0.43 & 9.4 \times 10^{-6} \\ \mbox{transcription factor} \\ \mbox{NGDN} & 14 & 23406695 & 40174 & PC \\ \mbox{Neugoidin} & -0.05 & 0.07 & 4.8 \times 10^{-1} & -0.27 & 0.07 & 4.4 \times 10^{-5} \\ \mbox{PDESB} & 5 & 77104449 & 219359 & PC \\ \mbox{Polyabe} & Polynokiesterase 8b & 0.23 & 0.13 & 8.6 \times 10^{-2} & 1.90 & 0.41 & 3.8 \times 10^{-5} \\ \mbox{PNPLA3} & 22 & 43232792 & 40607 & PC \\ \mbox{Patarall like phospholipase domain} \\ \mbox{Long 1.9 & 1.04 & 9213781 & 175214 & PC \\ \mbox{Ras and rab interactor 3} & -0.44 & 0.11 & 3.7 \times 10^{-5} & -0.85 & 0.38 & 2.5 \times 10^{-2} \\ \mbox{SAA1} & 11 & 18239223 & 9421 & PC \\ \mbox{SAA2} & 11 & 18239223 & 9421 & PC \\ \mbox{SAA2} & 11 & 18239223 & 9421 & PC \\ \mbox{SAA2} & 11 & 18239223 & 9421 & PC \\ \mbox{SaA2} & 2.00 & 0.44 & 1.7 \times 10^{-6} & 1.24 & 0.30 & 6.5 & 10^{-5} \\ \mbox{SAA2} & 11 & 18239223 & 9421 & PC \\ \mbox{SAA2}$	LINC00211	2	37820498	55777	lncRNA	Long intergenic non-protein coding	2.14	0.50	$1.7 \times 10^{-5}$	0.02	0.26	$9.4 \times 10^{-1}$
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$						rna 211						
$ \begin{array}{c} \mbox{rm 626} \\ \mbox{IRRM3} & 7 & 111091006 & 34 449 & PC & Leucine rich repeats and & 0.50 & 0.31 & 1.1 \times 10^{-1} & 2.95 & 0.68 & 1.2 \times 10^{-5} \\ \mbox{LRTM1} & 3 & 54918231 & 48858 & PC & Leucine rich repeats and & 0.50 & 0.31 & 1.1 \times 10^{-1} & 2.95 & 0.68 & 1.2 \times 10^{-5} \\ \mbox{LRTM5} & 2 & 111898607 & 130955 & PC & Mer proto-oncogene, tyrosine kinase & -0.63 & 0.14 & 4.1 \times 10^{-6} & -0.80 & 0.29 & 5.8 \times 10^{-3} \\ \mbox{MTCO3P39} & 4 & 49246021 & 518 & PP & Mt-o3 pseudogene 39 & - & - & 0.94 & 0.21 & 7.1 \times 10^{-6} \\ \mbox{MTND3P22} & 4 & 49246601 & 315 & PP & Mt-o3 pseudogene 39 & - & - & 0.94 & 0.21 & 7.1 \times 10^{-6} \\ \mbox{MVCL} & 1 & 39895426 & 6831 & PC & Mucin 19, oligomeric & -0.37 & 0.39 & 3.5 \times 10^{-1} & 3.22 & 0.77 & 2.7 \times 10^{-5} \\ \mbox{MYCL} & 1 & 39895426 & 6831 & PC & Mycl proto-oncogene, blh & 1.40 & 0.36 & 1.1 \times 10^{-4} & 1.90 & 0.43 & 9.4 \times 10^{-6} \\ \mbox{MYCL} & 1 & 39895426 & 6831 & PC & Mycl proto-oncogene, blh & 1.40 & 0.36 & 6.1 \times 10^{-4} & 1.90 & 0.41 & 3.8 \times 10^{-6} \\ \mbox{PDE8B} & 5 & 77210449 & 219359 & PC & Phosphodiesterase 8b & 0.23 & 0.13 & 8.6 \times 10^{-1} & -0.27 & 0.07 & 4.4 \times 10^{-5} \\ \mbox{PDE8B} & 5 & 77210449 & 219359 & PC & Phosphodiesterase 8b & 0.23 & 0.13 & 8.6 \times 10^{-1} & 1.42 & 0.35 & 5.6 \times 10^{-5} \\ \mbox{PDE1A3} & 22 & 43923792 & 40097 & PC & Patatin like phospholipase domain & 1.98 & 0.44 & 6.4 \times 10^{-6} & 1.42 & 0.35 & 5.6 \times 10^{-5} \\ \mbox{RBM44} & 2 & 237798389 & 44420 & PC & Raa binding motif protein 44 & 0.52 & 0.12 & 1.1 \times 10^{-5} & 0.07 & 0.28 & 7.9 \times 10^{-1} \\ \mbox{RIN3} & 14 & 92513781 & 175214 & PC & Raa and rab interactor 3 & -0.44 & 0.11 & 3.7 \times 10^{-5} & -0.85 & 0.38 & 2.5 \times 10^{-2} \\ \mbox{SAA1} & 11 & 18230223 & 9421 & PC & Serum amyloid a1 & 3.05 & 0.53 & 0.3 \times 10 \times 10^{-2} & 2.40 & 0.36 \times 10^{-5} \\ \mbox{SAA2} & 11 & 18230223 & 9421 & PC & Serum amyloid a2 & 2.09 & 0.44 & 1.7 \times 10^{-6} & 1.24 & 0.30 & 6.5 \times 10^{-5} \\ \mbox{SIROOM3} & 7 & 76435229 & 348025 & PC & Sloroom family member 3 & 0.85 & 0.33 & 1.0 \times 10^{-2} & 2.26 & 0.66 & 2.2 \times$	LINC00626	1	168784012	8875	lncRNA	Long intergenic non-protein coding	_	_	_	3.62	0.71	$3.8  imes 10^{-7}$
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$						rna 626						
LRTM1 3 54918231 48858 PC Leucine rich repeats and 0.50 0.31 $1.1 \times 10^{-1}$ 2.95 0.68 $1.2 \times 10^{-5}$ transmuthrate domains 1 MERTK 2 111898607 130955 PC Mer proto-oncogene, tyrosine kinase $-0.63$ 0.14 $4.1 \times 10^{-6}$ $-0.80$ 0.29 5.8 $\times 10^{-3}$ MTCO3P39 4 49246021 518 PP Mt-co3 pseudogene 39 $  -$ 0.94 0.21 7.1 $\times 10^{-6}$ MTND3P22 4 4924601 315 PP Mt-u3 pseudogene 22 $   -$ 1.18 0.28 2.9 $\times 10^{-5}$ MYCL 1 39895426 6831 PC Mycl proto-oncogene, bhlh 1.40 0.36 $1.1 \times 10^{-4}$ 1.90 0.43 9.4 $\times 10^{-6}$ transcription factor NGDN 14 23469689 40174 PC Neuroguidin $-0.05$ 0.07 4.8 $\times 10^{-1}$ $-0.27$ 0.07 4.4 $\times 10^{-6}$ PDESB 5 77210449 219359 PC Phosphodiesterase 8b 0.23 0.13 8.6 $\times 10^{-2}$ 1.90 0.41 3.8 $\times 10^{-6}$ PPIPLA3 22 43923792 40697 PC Paternally expressed 10 0.62 0.22 5.7 $\times 10^{-3}$ 1.48 0.37 5.8 $\times 10^{-5}$ PNPLA3 22 43923792 40697 PC Raa binding motif protein 44 0.52 0.12 $1.1 \times 10^{-6}$ 0.07 0.28 7.9 $\times 10^{-5}$ RBM44 2 237798389 44420 PC Raa binding motif protein 44 0.52 0.12 $1.1 \times 10^{-5}$ 0.07 0.28 7.9 $\times 10^{-5}$ RIN3 14 92513781 175214 PC Raa and rab interactor 3 $-0.44$ 0.11 $3.7 \times 10^{-5}$ 0.85 0.38 $2.5 \times 10^{-2}$ SAA1 11 18261260 3718 PC Serum amyloid a1 3.05 0.53 9.0 $\times 10^{-9}$ 3.40 0.57 1.9 $\times 10^{-9}$ SAA2 11 1823123 17213 PC Sa2-saA4 readthrough $         -$	LRRN3	7	111091006	34449	PC	Leucine rich repeat neuronal 3	0.27	0.16	$8.5  imes 10^{-2}$	1.43	0.34	$2.1  imes 10^{-5}$
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	LRTM1	3	54918231	48858	$\mathbf{PC}$	Leucine rich repeats and	0.50	0.31	$1.1 \times 10^{-1}$	2.95	0.68	$1.2 \times 10^{-5}$
$\begin{array}{llllllllllllllllllllllllllllllllllll$						transmembrane domains 1						
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	MERTK	2	111898607	130955	PC	Mer proto-oncogene, tyrosine kinase	-0.63	0.14	$4.1 \times 10^{-6}$	-0.80	0.29	$5.8  imes 10^{-3}$
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	MTCO3P39	4	49246021	518	PP	Mt-co3 pseudogene 39	-	—	—	0.94	0.21	$7.1 \times 10^{-6}$
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	MTND3P22	4	49246601	315	PP	Mt-nd3 pseudogene 22	-	—	—	1.18	0.28	$2.9 \times 10^{-5}$
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	MUC19	12	40393395	177438	$\mathbf{PC}$	Mucin 19, oligomeric	-0.37	0.39	$3.5 \times 10^{-1}$	3.22	0.77	$2.7 \times 10^{-5}$
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	MYCL	1	39895426	6831	PC	Mycl proto-oncogene, bhlh	1.40	0.36	$1.1 \times 10^{-4}$	1.90	0.43	$9.4 \times 10^{-6}$
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$						transcription factor			1			
PDESB       5       77210449       219359       PC       Phosphodiesterase 8b       0.23       0.13       8.6 $\times 10^{-4}$ 1.90       0.41       3.8 $\times 10^{-6}$ PEG10       7       94 656 325       13371       PC       Paternally expressed 10       0.62       0.22       5.7 $\times 10^{-3}$ 1.48       0.37       5.8 $\times 10^{-5}$ PNPLA3       22       43 923 792       40 697       PC       Paternally expressed 10       0.62       0.22       5.7 $\times 10^{-3}$ 1.48       0.37       5.8 $\times 10^{-5}$ RBM44       2       237 798 389       44 420       PC       Ras and rab interactor 3       -0.44       0.11       3.7 $\times 10^{-5}$ -0.85       0.38       2.5 $\times 10^{-2}$ SAA1       11       18 266 260       3718       PC       Serum anyloid a1       3.05       0.53       9.0 $\times 10^{-9}$ 3.40       0.57       1.9 $\times 10^{-9}$ SAA2       11       18 239 23       942       PC       Shoom family member 3       0.85       0.33       1.0 $\times 10^{-2}$ 2.72       0.61       6.9 $\times 10^{-6}$ SHROOM3       4       76 435 229       348 052       PC       Shoom family member 3       0.85       0.33       1.0 $\times 10^{-2}$	NGDN	14	23469689	40174	PC	Neuroguidin	-0.05	0.07	$4.8 \times 10^{-1}$	-0.27	0.07	$4.4 \times 10^{-3}$
PEG10       7       94656 325       13 371       PC       Paternally expressed 10       0.62       0.22       5.7 × 10 <sup>-5</sup> 1.48       0.37       5.8 × 10 <sup>-9</sup> PNPLA3       22       43 923 792       40 697       PC       Patatin like phospholipase domain containing 3       1.98       0.44       6.4 × 10 <sup>-6</sup> 1.42       0.35       5.6 × 10 <sup>-5</sup> RBM44       2       237 798 389       44 420       PC       Ra binding motif protein 44       0.52       0.12       1.1 × 10 <sup>-5</sup> 0.07       0.28       7.9 × 10 <sup>-1</sup> SAA1       11       18 266 260       3718       PC       Saru and rab interactor 3       -0.44       0.11       3.7 × 10 <sup>-5</sup> -0.85       0.38       2.5 × 10 <sup>-2</sup> SAA2       11       18 266 260       3718       PC       Saru and rab interactor 3       -0.44       0.11       3.7 × 10 <sup>-6</sup> 3.40       0.57       1.9 × 10 <sup>-9</sup> SAA2       11       18 239 223       9421       PC       Sara2-saa4 readthrough       -       -       -       -       4.01       0.75       8.0 × 10 <sup>-8</sup> SHROOM3       4       76 435 229       348 052       PC       Shroon family member 3       0.85       0.31       0.10 × 10 <sup>-2</sup>	PDE8B	5	77210449	219359	PC	Phosphodiesterase 8b	0.23	0.13	$8.6 \times 10^{-2}$	1.90	0.41	$3.8 \times 10^{-6}$
PNPLA3224392379240097PCPatatin like phospholpase domain1.98 $0.44$ $6.4 \times 10^{-5}$ $1.42$ $0.35$ $5.6 \times 10^{-5}$ RBM442237798 38944420PCRna binding motif protein 44 $0.52$ $0.12$ $1.1 \times 10^{-5}$ $0.07$ $0.28$ $7.9 \times 10^{-1}$ RIN31492513781175214PCRas and rab interactor 3 $-0.44$ $0.11$ $3.7 \times 10^{-5}$ $-0.85$ $0.38$ $2.5 \times 10^{-2}$ SAA111182662603718PCSerum anyloid a1 $3.05$ $0.53$ $9.0 \times 10^{-9}$ $3.40$ $0.57$ $1.9 \times 10^{-9}$ SAA211182392239421PCSac2-saat roadthrough $   4.01$ $0.75$ $8.0 \times 10^{-8}$ SHROOM3476435229348025PCShroom family member 3 $0.85$ $0.33$ $1.0 \times 10^{-2}$ $2.72$ $0.61$ $6.9 \times 10^{-6}$ SP1125338017636271PCSpl transcription factor $-0.12$ $0.05$ $1.9 \times 10^{-2}$ $-0.26$ $0.62$ $2.2 \times 10^{-5}$ SYT15104657821715957PCSynaptotagmin 15 $-0.13$ $0.18$ $4.7 \times 10^{-1}$ $-1.25$ $0.28$ $1.2 \times 10^{-5}$ TDO241558473865669PCTryptophan 2,3-dioxygenase $2.76$ $0.63$ $1.3 \times 10^{-5}$ $0.27$ $7.3 \times 10^{-4}$ vseudogene	PEG10	7	94 656 325	13 371	PC	Paternally expressed 10	0.62	0.22	$5.7 \times 10^{-3}$	1.48	0.37	$5.8 \times 10^{-5}$
Containing 3Containing 3RBM44223779838944420PCRa binding motif protein 440.520.12 $1.1 \times 10^{-5}$ 0.070.28 $7.9 \times 10^{-1}$ RIN31492513781175214PCRa and rab interactor 3 $-0.44$ 0.11 $3.7 \times 10^{-5}$ $-0.85$ 0.38 $2.5 \times 10^{-2}$ SAA11118 2662603718PCSerun anyloid a1 $3.05$ $0.53$ $9.0 \times 10^{-9}$ $3.40$ $0.57$ $1.9 \times 10^{-9}$ SAA21118 23142317213PCSaa2-saa4 readthrough $   4.01$ $0.75$ $8.0 \times 10^{-8}$ SAA21118 2392239421PCSerum anyloid a2 $2.09$ $0.44$ $1.7 \times 10^{-6}$ $1.24$ $0.30$ $3.6 \times 10^{-6}$ SHROOM3476 435 229348025PCShroom family member 3 $0.85$ $0.33$ $1.0 \times 10^{-2}$ $2.72$ $0.61$ $6.9 \times 10^{-6}$ SU217421719 67828840602PCSpl transcription factor $-0.12$ $0.05$ $1.9 \times 10^{-2}$ $-0.6$ $0.22 \times 10^{-5}$ SP11253 380 176 $36271$ PCSpl transcription factor $-0.13$ $0.18$ $4.7 \times 10^{-1}$ $-1.25$ $0.28$ $1.2 \times 10^{-5}$ TDO24155 85473865669PCTryptophan 2,3-dioxygenase $2.76$ $0.63$ $1.3 \times 10^{-5}$ $4.23$ $0.79$ $8.8 \times 10^{-8}$ voimeroansal 1 re	PNPLA3	22	43923792	40697	PC	Patatin like phospholipase domain	1.98	0.44	$6.4 \times 10^{-6}$	1.42	0.35	$5.6 \times 10^{-5}$
RBM44       2       237 / 88 389       44 420       PC       Rha binding motil protein 44       0.52       0.12       1.1 × 10 <sup>-5</sup> 0.07       0.28 $r, 9 \times 10^{-5}$ SAA1       11       18 266 260       3718       PC       Sas and rab interactor 3 $-0.44$ 0.11 $3.7 \times 10^{-5}$ $-0.85$ $0.38$ $2.5 \times 10^{-2}$ SAA2       11       18 231 423       17 213       PC       Sasa2-saa4 readthrough $    4.01$ $0.75$ $8.0 \times 10^{-8}$ SAA2       11       18 239 223       9421       PC       Sasa2-saa4 readthrough $     4.01$ $0.75$ $8.0 \times 10^{-8}$ SHROOM3       4       76 435 229       348 025       PC       Slroom family member 3 $0.85$ $0.33$ $1.0 \times 10^{-2}$ $2.72$ $0.61$ $6.9 \times 10^{-6}$ SLC47A2       17       19 678 288       40 692       PC       Solute carrier family 47 member 2 $1.43$ $0.27$ $1.1 \times 10^{-7}$ $3.17$ $0.51$ $4.3 \times 10^{-10}$ SP1       12       53 380 176       36 271       PC       Splaptotag	DDM	0	007 700 000	44.400	DC	contaming 3	0.50	0.10	1.1 10-5	0.07	0.00	7.0 10-1
RIN3       14       92513 (81       175214       PC       Kas and rab interactor 3 $-0.44$ 0.11 $3.7 \times 10^{-9}$ $-0.85$ $0.38$ $2.5 \times 10^{-9}$ SAA1       11       18266260       3718       PC       Serum anyloid a1 $3.05$ $0.53$ $9.0 \times 10^{-9}$ $3.40$ $0.57$ $1.9 \times 10^{-9}$ SAA2       11       18231 423       17213       PC       Saa2-saa4 readthrough $   4.01$ $0.75$ $8.0 \times 10^{-8}$ SAA2       11       18231 423       17213       PC       Serum anyloid a2 $2.09$ $0.44$ $1.7 \times 10^{-6}$ $1.24$ $0.30$ $3.6 \times 10^{-5}$ SHROOM3       4       76435229       348025       PC       Shroom family member 3 $0.85$ $0.33$ $1.0 \times 10^{-2}$ $2.72$ $0.61$ $6.9 \times 10^{-6}$ SLC47A2       17       19678288       40692       PC       Solute carrier family 47 member 2 $1.43$ $0.27$ $1.1 \times 10^{-7}$ $3.17$ $0.51$ $4.3 \times 10^{-10}$ SP1       12       53380 176       36211       PC       Sp1 transcription factor $-0.12$ $0.051$ <td>RBM44</td> <td>2</td> <td>237 798 389</td> <td>44 420</td> <td>PC</td> <td>Rna binding motif protein 44</td> <td>0.52</td> <td>0.12</td> <td><math>1.1 \times 10^{-5}</math></td> <td>0.07</td> <td>0.28</td> <td><math>7.9 \times 10^{-1}</math></td>	RBM44	2	237 798 389	44 420	PC	Rna binding motif protein 44	0.52	0.12	$1.1 \times 10^{-5}$	0.07	0.28	$7.9 \times 10^{-1}$
SAA1       11       18 200 200       318       PC       Serum anyloid a1 $3.05$ $0.53$ $9.0 \times 10^{-5}$ $3.40$ $0.51$ $1.9 \times 10^{-5}$ SAA2-SAA4       11       18 231 423       17 213       PC       Saa2-saa4 readthrough $  -$	RIN3	14	92 913 781	1/5214	PU	Ras and rab interactor 3	-0.44	0.11	$3.7 \times 10^{-9}$	-0.85	0.38	$2.5 \times 10^{-2}$
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	SAAL	11	18 200 200	3/18	PU	Serum allyfold all	3.00	0.83	9.0 X 10 °	3.40 4.01	0.07	$1.9 \times 10^{-8}$
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	SAA2-SAA4	11	10 201 420	17213	PU PC	Saa2-saa4 reactinougn Sorum amyloid a2	2.00	0.44	$1.7 \times 10^{-6}$	4.01	0.70	$3.0 \times 10^{-5}$
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	SHROOMP	11	10 200 220 76 495 990	3421 349.09F		Shroom family member 2	⊿.09 0.95	0.44	$1.7 \times 10^{\circ}$ $1.0 \times 10^{-2}$	9.79	0.30	$6.0 \times 10^{-6}$
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	SILC47A9	4 17	10400229	040 020 40 609	FU DC	Soluto carrier family 47 member 9	0.00	0.00	$1.0 \times 10^{-7}$ $1.1 \times 10^{-7}$	2.12	0.01	4 3 × 10 °
Theorem         <	SEC41A2	19	19070400 53380176	36 971	PC	Spl transcription factor	_0.12	0.47	$1.1 \times 10^{-1}$ $1.0 \times 10^{-2}$	-0.26	0.01	$-1.0 \times 10^{-5}$
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	SYT15	10	46 578 917	15 957	PC	Synaptotagmin 15	-0.12	0.05	$4.7 \times 10^{-1}$	-1.25	0.00	$1.2 \times 10^{-5}$
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	TDO2	4	155 854 738	65 669	PC	Tryptophan 2.3-dioxygenase	2.76	0.63	$1.3 \times 10^{-5}$	4 23	0.20	$8.8 \times 10^{-8}$
pseudogene Dirio Oli 10.01 0.20 1.3 10	VN1B83P	19	21 289 554	445	UP	Vomeronasal 1 receptor 83	0.70	0.05	$4.5 \times 10^{-5}$	0.67	0.20	$7.3 \times 10^{-4}$
				- 10		pseudogene						

- 650 Table 2. Enriched gene ontology (GO) terms for both Salmon and STAR models, as generated from
- TopGO. The total number of annotated genes from the greater set is followed by the number of those
- which are significantly differentially expressed, as well as the enrichment of the term as calculated by
- Fisher's exact test. Significant/background genes are subset to those with GO terms (27/14475 for
- salmon and 19/13588 for STAR).

GO.ID	Term	Annotated	Significant	Expected	Fisher $p$
Salmon					
GO:0006953	Acute-phase response	30	2: SAA1, SAA2	0.06	$1.4  imes 10^{-3}$
GO:0055008	Cardiac muscle tissue morphogenesis	53	2: ANKRD1, ACTC1	0.10	$-4.4  imes 10^{-3}$
GO:0051965	Positive regulation of synapse assembly	55	2: LRTM1, LRRN3	0.10	$-4.7 imes10^{-3}$
GO:0090130	Tissue migration	271	2: ACTC1, SP1	0.51	$7.3  imes 10^{-3}$
GO:0045607	Regulation of inner ear auditory receptor cell differentiation	5	1: MYCL	0.01	$-9.3 imes10^{-3}$
GO:0019441	Tryptophan catabolic process to kynurenine	5	1: TDO2	0.01	$9.3  imes 10^{-3}$
GO:0036155	Acylglycerol acyl-chain remodeling	5	1: PNPLA3	0.01	$9.3 imes10^{-3}$
GO:0070814	Hydrogen sulfide biosynthetic process	5	1: SP1	0.01	$9.3\times10^{-3}$
STAR					
GO:0006953	Acute-phase response	25	2: SAA1, SAA2	0.03	$5.5 imes10^{-4}$
GO:1903566	Positive regulation of protein localization to cilium	5	1: EFCAB7	0.01	$7.0 imes10^{-3}$
GO:0097350	Neutrophil clearance	5	1: MERTK	0.01	$7.0  imes 10^{-3}$
GO:0036155	Acylglycerol acyl-chain remodeling	6	1: PNPLA3	0.01	$8.4  imes 10^{-3}$
GO:0060385	Axonogenesis involved in innervation	6	1: COL25A1	0.01	$8.4 \times 10^{-3}$
GO:0051798	Positive regulation of hair follicle development	7	1: FST	0.01	$9.7  imes 10^{-3}$
GO:0048630	Skeletal muscle tissue growth	7	1: CHRNA1	0.01	$9.7  imes 10^{-3}$
GO:1901072	Glucosamine-containing compound catabolic process	7	1: CHI3L1	0.01	$9.7\times10^{-3}$

# 656 Supplemental Information

- 657 **Primary supplement**. PDF. Figures S1-S10 and Table S1, S3-S5.
- **Table S2**. Excel. Complete list of transcriptome-wide genes for each model in each tissue type as well
- as their test statistics.
- 660
- 661 Table S6. Excel. Differentially expressed isoforms as estimated from the IsoformSwitchAnalyzeR
- 662 implementation of DEXSeq.